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Resumo 
 
O sucesso dos receptores acoplados à proteína G (GPCRs) enquanto alvos 
terapêuticos para o tratamento de doenças do sistema nervoso central torna estes receptores 
alvos pertinentes de investigação. Especificamente, a activação de receptores mGlu2 tem 
mostrado reduzir a transmissão glutamatérgica em áreas do cerebro onde o excesso de 
sinalização glutamatérgica parece estar implicado na patofisiologia de doenças como a 
ansiedade e a esquizofrenia. Deste modo, a activação dos receptores mGlu2 está actualmente 
a ser encarada como uma potencial estratégia para o tratamento destas doenças. Diversos 
moduladores alostéricos positivos (PAMs), que se ligam a um local do receptor diferente do 
local de ligação do glutamato, têm revelado modular os receptores mGlu2 de uma forma 
selectiva. Com o objectivo de identificar aminoácidos potencialmente importantes para a 
interacção entre o PAM e o receptor mGlu2, foi efectuada a modelação molecular e o 
docking de PAMs de receptores mGlu2 em paralelo com mutagénese dirigida. Receptores 
mGlu2 mutantes foram produzidos e o impacto dessas mutações na actividade de diversos 
PAMs foi avaliado, de forma a confirmar o papel destes aminoácidos na actividade destes 
compostos. Este estudo identifica aminoácidos importantes para a actividade dos PAMs e 
sugere um potencial local de ligação destes compostos. 
 
 
 
 
Palavras-chave: GPCR, receptor mGlu2, alosterismo, modulador alostérico positivo, 
mutagénese.   
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Abstract 
 
The proven success of G protein-coupled receptors (GPCRs) as drug targets for the 
treatment of CNS disorders renders them attractive targets of research. Specifically, 
activation of the G protein-coupled or metabotropic glutamate (mGlu2) receptor has been 
shown to reduce glutamatergic transmission in brain regions where excess glutamate 
signaling may be implicated in the pathophysiology of disorders such as anxiety and 
schizophrenia. Hence, activation of the mGlu2 receptor is being pursued as a novel 
therapeutic approach for the treatment of these diseases. Multiple positive allosteric 
modulators (PAMs), which bind to a site other than that of the endogenous mGlu2 receptor 
agonist glutamate, have been shown to modulate mGlu2 receptors in a selective way. In order 
to identify amino acids potentially important for the interaction between PAMs and the 
mGlu2 receptor, homology modelling and docking of mGlu2 receptor PAMs was performed 
in parallel with experimental site directed mutagenesis. Mutant mGlu2 receptors were 
produced and the impact of the selected receptor mutations on the activity of several PAM 
compounds towards the receptor was evaluated, in order to confirm the role of these amino 
acids in the activity of the compounds. This study identifies crucial amino acids for the 
activity of mGlu2 receptor PAMs and suggests a potential binding pocket of PAMs. 
 
 
 
 
Keywords: GPCR, mGlu2 receptor, allosterism, positive allosteric modulator, mutagenesis. 
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Chapter 1 
Introduction
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1.1. G Protein-Coupled Receptors 
 
Membrane-bound receptors have a leading role in the recognition of intercellular 
messenger molecules and sensory messages, which makes them fundamental for the 
communication of the cells with each other and with the environment (Bockaert and Pin, 
1999). They have been classified into several families, the most common of which is the G 
Protein-Coupled Receptors (GPCR) family (Bockaert and Pin, 1999). GPCRs currently 
constitute one of the principal drug targets in pharmacology (Vauquelin and von Mentzer, 
2007; Urwyler, 2011). More than 50% of the marketed therapeutics are based on GPCRs, and 
a large share of total drug sales and prescriptions (~25%) are directed at these receptors 
(Lündstrom and Chiu, 2006), rendering them important and pertinent targets of research. 
GPCRs constitute one of the largest and most diverse protein superfamilies (Urwyler, 
2011). Human genome sequencing has revealed that more than 1000 genes encode GPCRs, 
which represents a substantial part (± 3%) of the human genome (Vauquelin and von 
Mentzer, 2007). Vassilatis et al., (2003) proposed that 367 human GPCRs have endogenous 
ligands (‘endoGPCRs’), 143 of which are orphan receptors (i.e. receptors with no known 
ligand). The remaining receptors are chemosensory (taste, odorant or pheromone receptors), 
and they respond only to sensory signals of external origin (Vassilatis et al., 2003; Urwyler, 
2011). 
GPCRs are receptors for a variety of extracellular stimuli, such as hormones, 
neurotransmitters, chemokines, calcium ions, light, odorants (Lündstrom and Chiu, 2006), 
pheromones, gustative molecules, lipids, peptides, proteins (Urwyler, 2011), small molecules 
including amino-acid residues and nucleotides (Figure 1). Upon binding of these ligands, they 
mediate several cellular signal transduction events that are crucial for the cells, tissues, 
organs and whole organisms to react properly to environmental requirements (Bockaert and 
Pin, 1999).  
GPCRs regulate different physiological processes that affect neurological and 
neurodegenerative functions, cardiovascular mechanisms and metabolic control (Lündstrom 
and Chiu, 2006).  
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1.1.1. GPCR structure 
 
GPCRs consist of a single peptide, whose length can vary from 400 to 1200 amino-
acids (Vauquelin and von Mentzer, 2007). They have in common a central core domain 
composed of seven transmembrane α-helices (TM1 – TM7) connected by three intracellular 
(IL1 – IL3) and three extracellular (EL1 – EL3) loops (Baldwin, 1993). Each GPCR 
possesses also an extracellular N-terminal domain and an intracellular C-terminal domain 
(Lündstrom and Chiu, 2006) (Figure 1). The length and function of the N- and C- terminal 
domains and of the intracellular loops varies between the different GPCRs and each of these 
domains confers specific properties to these receptor proteins (Bockaert and Pin, 1999).  Two 
cystein residues, one in EL1 and the other in EL2, are conserved in most GPCRs. These two 
residues form a disulfide bond which is thought to be important for the packing and 
stabilization of a restricted number of conformations of the seven TMs (Bockaert and Pin, 
1999). 
 
 
  
Figure 1: Diversity of messages which activate G-protein 
Coupled Receptors (GPCRs). GPCRs have a central 
common core made of seven transmembrane helices 
(TM1-7) connected by three intracellular (i1, i2, i3) and 
three extracellular (e1, e2, e3) loops. Bockaert and Pin, 
1999 
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1.1.2. GPCR mode of action – signaling pathways 
  
GPCRs become functionally active when coupled to guanine nucleotide-binding 
proteins (G proteins). Typically, the receptor is in its resting or low affinity state in the 
absence of agonists. This inactive conformation is caused by a number of intramolecular 
constraining interactions (Vauquelin and von Mentzer, 2007). Upon agonist binding to the 
receptor, a modification in these constraints occurs, leading to a shift in the receptor 
conformation. The receptor is now in an active state that leads to the formation of a complex 
with intracellular G proteins. 
G proteins constitute a family of closely related membrane-associated polypeptides 
(Vauquelin and von Mentzer, 2007). They are heterotrimeric proteins that consist of a 
guanine nucleotide binding Gα subunit (38-52 kDa), a Gβ subunit (35 kDa) and a Gγ (8-10 
kDa) subunit. G proteins are anchored to the cytoplasmic side of the plasma membrane 
(Vauquelin and von Mentzer, 2007). The β and γ subunit are always closely associated, thus 
creating a βγ complex that is presumed to be interchangeable from one G protein to another 
(Vauquelin and von Mentzer, 2007). Gα subunit is predominantly hydrophilic but it is 
anchored to the plasma membrane through its coupling to the βγ complex; this subunit 
constitutes the receptor-recognizing part of G proteins (Vauquelin and von Mentzer, 2007). 
As previously mentioned, in the resting state the receptor and the G protein do not 
interact with each other. In this state, Gα subunit contains tightly bound guanosine-5’-
diphosphate (GDP) (Vauquelin and von Mentzer, 2007). Once an agonist binds to the 
receptor, the conformation of the receptor changes which enables the interaction of the 
receptor with the Gα subunit of the G protein. GDP is then released and replaced by 
guanosine-5’-triphosphate (GTP), and the Gα subunit is dissociated from the Gβγ dimer. Gα 
subunit and Gβγ dimer can then both activate cellular effector molecules (Lündstrom and 
Chiu, 2006). The G-protein linked effector components are either enzymes or ion channels 
(Table 1). 
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Table 1: Principal G protein subunits and their primary effectors (Adapted from Hermans, 2003) 
Subunit Family Main Subtypes Primary effector 
α αS GαS, Gαolf + Adenylyl cyclase 
 αi/o Gαi-1, Gαi-2, Gαi-3 - Adenylyl cyclase 
  GαoA, GαoB + K
+ channels 
  Gαt1, Gαt2 - Ca
2+ channels 
  Gαz Cyclic GMP 
   + Phosphodiesterase 
 αq/11 Gαq, Gα11, Gα14 - Phospholipase C 
  Gα15, Gα16  
 α12 Gα12, Gα13 ? 
β β1-5 (6) Different assemblies  
of β/γ subunits  
+/- Adenylyl cyclase 
  
+ Phospholipases 
Phosphatidylinositol 
  + 3-kinase 
γ γ1-11 (12)  + Protein kinase C 
   + Protein kinase D 
   + GPCR kinases 
   Ca2+, K+ (and Na+) channels 
 
 
The Gα subunit possesses an endogenous GTPase activity, which will cause GTP 
hydrolysis into GDP and lead to the termination of receptor activity. Rapid termination of 
GPCR function can occur also through other mechanisms. One of them is receptor 
phosphorylation mediated by Protein Kinase A (PKA) or Protein Kinase C (PKC), which will 
lead to the uncoupling of the receptor and the G protein. Another mechanism involves G 
protein-coupled receptor kinases (GRKs) which can only phosphorylate the receptor when it 
is activated or agonist-occupied, stabilizing a conformation state necessary for the interaction 
of the GPCR with arrestins. Binding of arrestin prevents further GPCR and G protein 
interactions or leads to receptor endocytosis. Receptor degradation in lysosomes can also 
occur, as well as regulation of gene transcription or translation. At a post-expression level, 
regulators of G protein signaling (RGS) serve as GTPase-activating proteins for G proteins, 
enhancing the hydrolysis rate of GTP and thus leading to termination of receptor activity 
(Lündstrom and Chiu, 2006). 
GPCRs are known to induce signaling pathways not only through direct interaction 
with G proteins, but also through interaction with other proteins. These alternative signaling 
pathways may confer a higher specificity to the GPCR signaling and may also allow distinct 
physiological functions of the different GPCRs (Lündstrom and Chiu, 2006). Arrestins act as 
adapters or scaffolds for signaling proteins involved in the ERK/mitogen-activated protein 
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kinase signaling pathway (Vauquelin and von Mentzer, 2007). GPCRs have also been 
suggested to interact with the family of the PDZ domain-containing proteins (Kornau et al., 
1997).  Several GPCRs interact with members of the janus kinase (JAK) family of 
nonreceptor protein tyrosine kinases, which will recruit and phosphorylate members of the 
STAT (signal transducers and activators of transcription) family of transcription factors 
(Ritter and Hall, 2009).  
 
 
1.1.3. Families of GPCRs 
 
GPCRs are presumed to have evolved from a common ancestor (Vauquelin and von 
Mentzer, 2007). They have been classified into several families/classes based on sequence 
and structural similarity (Lündstrom and Chiu, 2006, Vauquelin and von Mentzer, 2007 and 
Yarnitzky et al., 2010).  
 
 
1.1.3.1. Family A or Class 1 GPCRs 
 
Family A is the largest group of GPCRs and the subfamily of rhodopsin/β2-adrenegic 
receptor-like receptors is by far the most studied (Vauquelin and von Mentzer, 2007). Family 
A consists of light receptors (rhodopsin), adrenaline receptors and olfactory receptors. The 
homology among the members of this family is overall low (Vauquelin and von Mentzer, 
2007) but they all possess an arginine in the highly conserved Asp/Glu-Arg-Tyr (D/ERY) 
motif positioned at the cytoplasmic side of TM3 (Figure 2) (Lündstrom and Chiu, 2006, 
Vauquelin and von Mentzer, 2007). The ligands of family A GPCRs bind within the 7TM 
domain. 
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1.1.3.2. Family B or Class 2 GPCRs 
  
Based on the homology shared by family B receptors (Vauquelin and von Mentzer, 
2007), they were divided in three subfamilies: subfamily B1) those recognizing peptide 
hormones (secretin, glucagon, VIP (Vauquelin and von Mentzer, 2007), calcitonin and 
corticotrophin-releasing (Lündstrom and Chiu, 2006) hormone receptor family), B2) those 
containing a GPCR proteolytic site domain (so far, orphan receptors) and B3) those with 
cystein-rich domains (frizzled and smoothened receptors) (Vauquelin and von Mentzer, 
2007). Family B receptors have a propensity to associate with partner/accessory proteins 
(Vauquelin and von Mentzer, 2007). For the subfamily of secretin/glucagon/VIP receptors, it 
is shown that the N-terminal domain is required for ligand binding (Unson et al., 1995).  
 
 
1.1.3.3. Family C or Class 3 GPCRs 
  
Family C receptors include γ-amino butyric acid (GABA) receptors, calcium-sensing 
receptors, three receptors involved in taste perception and metabotropic glutamate (mGlu) 
receptors, which represent the focus of this thesis (Vauquelin and von Mentzer, 2007; 
Lündstrom and Chiu, 2006). 
 
 
Figure 2: Two-dimensional structure of family A GPCRs and 
rhodopsin. Adapted from Vauquelin and von Mentzer, 2007. 
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The typical feature of this GPCR family is the exceptionally large extracellular N-
terminal region (600 amino acids; Vauquelin and von Mentzer, 2007) that is essential for 
ligand binding and receptor activation (Lündstrom and Chiu, 2006) (Figure 3A).  The large 
extracellular N-terminal domain is also termed the Venus flytrap domain (VFD) (Pin et al., 
2003), which is connected to the 7TM domain through a cystein-rich domain (CRD), 
composed of nine conserved cysteins and present in all family C receptors, except for 
GABAB receptors (Vauquelin and von Mentzer, 2007; Niswender and Conn, 2010). Each 
VFD is composed of two lobes, and the cleft between them constitutes the binding site for the 
natural messenger (Vauquelin and von Mentzer, 2007, Niswender and Conn, 2010) (Figure 
3B). Interestingly, the VFD shares sequence similarity with bacterial periplasmic-binding 
proteins, which are involved in the transport of small molecules (Vauquelin and von Mentzer, 
2007). The TM loops of family C GPCRs show an overall low sequence similarity with the 
homologous loops of family A. However, the two families share several conserved amino 
acid residues, as well as a conserved disulfide bond between the top of TM3 and the second 
extracellular loop, suggesting a common ancestor gene for both and, for family C GPCRs, a 
fusion of that gene with the gene for a periplasmic-binding protein (Vauquelin and von 
Mentzer, 2007). 
Class C GPCRs have been found to form homo- and heterodimers (Vauquelin and von 
Mentzer, 2007). For mGlu receptors, there is evidence suggesting that they form homodimers 
stabilized by a disulphide bridge (through VFD or CRD). Accordingly, studies focusing on 
the structure of mGlu receptors revealed that the binding of the agonist to one or both 
domains induces large conformational changes (Jingami et al., 2003). There are three main 
A 
Figure 3: Structure of family C GPCRs. A) Two-dimensional structure of family C 
GPCRs and rhodopsin (Adapted from Vauquelin and von Mentzer, 2007); B) Family C 
GPCRs all have a common core composed of seven-transmembrane helices (the 7TM 
domain comprised of TM1-7) with a large, bilobal Venus flytrap extracellular N-terminal 
domain and an intracellular C-terminal domain. (Adapted from Urwyler, 2011). 
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configurations of the VFD dimer: open-open (inactive), which is stabilized by antagonists; 
open-closed and closed-closed, which are induced by the binding of the agonist to one or two 
protomers, respectively (Figure 4). The configuration of the flytrap domains is important for 
receptor activation; it has for example been shown that mutations in the residues that prevent 
closure of the VFD are capable of switching the pharmacology of antagonists to agonists 
(Bessis et al., 2002). In the case of mGlu receptors, VFDs not only bind glutamate, but also 
bind magnesium and calcium, which can potentiate or activate the receptor (Francesconi and 
Duvoisin 2004; Kubo et al., 1998; Kunishima et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Once an agonist binds to the VFD, it induces conformational changes that are propagated to 
the transmembrane domain (TM) and C-terminal tail, through the CRD (Huang et al., 2011). 
A binding pocket located in the TM is the binding site for the majority of characterized 
allosteric modulators (discussed in Section 1.3) of mGlu receptors, thus allowing the 
modulation of receptor activity by those ligands (Brauner-Osborne et al., 2007). The C-
terminal domain is target of alternative splicing, regulation by phosphorylation, and 
modulatory protein-protein interactions in several GPCRs, which make it an important region 
for the modulation of G protein coupling (Niswender and Conn, 2010; Bockaert and Pin, 
1999). 
Figure 4: Scheme of the mGlu receptor dimer in different activity states. mGlu receptor dimers 
possess two large extracellular domains called the Venus flytrap domains (VFDs), which bind 
glutamate and other so-called orthosteric ligands. The cysteine-rich domain links the VFDs to 
seven transmembrane-spanning domains; the C-terminus is intracellular and is often subject to 
alternative splicing to generate different C-terminal protein tails. The open-open state is the 
inactive state and can be stabilized by antagonists. One or both VFDs can bind glutamate, 
which will lead to active receptor conformations. Niswender and Conn, 2010 
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1.1.3.4. Families D, E and F or Class 4, 5 and 6 GPCRs 
  
The yeast pheromone receptors – families D (STE2 receptors) and E (STE3 receptors) 
and four cAMP receptors from Dictyostelium discoideum (family F) form three smaller 
families of GPCRs (Vauquelin and von Mentzer, 2007; Lündstrom and Chiu, 2006). 
 
 
1.1.4. GPCRs in the Central Nervous System - Overview 
 
GPCRs are widely expressed in the central nervous system (CNS) (Lündstrom and 
Chiu, 2006; Lim, 2007). They are expressed in different types of neurons and in astrocytes 
and glial cells, and mediate a slow modulation of neuronal activity, in contrast to ion 
channels, which mediate fast synaptic excitatory neurotransmission (Lündstrom and Chiu, 
2006, Dingledine et al., 1999). Postsynaptically, GPCRs can induce changes in intracellular 
cAMP levels, increase phosphoinositol turnover and/or indirectly modulate ion channel 
activity through the activation of kinases. Presynaptically, they act as autoreceptors to 
decrease the release of the respective neurotransmitter or as heteroreceptors that modulate the 
release of neurotransmitters other than their equivalent ligands (Lündstrom and Chiu, 2006). 
GPCRs play a critical role in developmental processes and synaptic transmission, and they 
also mediate other important physiological processes such as cognition, thought and 
emotional state, motor and hormonal control and pain sensation (Lündstrom and Chiu, 2006; 
Lim, 2007). 
Given the wide distribution of GPCRs in the CNS, their involvement in CNS 
disorders is expectable. Abnormalities in the regulation of GPCRs have been related to 
psychiatric disorders such as schizophrenia and mood disorders (Catapano and Manji, 2007). 
GPCRs have also been shown to play important roles in key neurotransmitter systems that are 
disrupted in Alzheimer’s disease and hence have been related to Alzheimer’s disease 
pathogenesis (Thathiah and De Strooper, 2011).  
GPCRs have been proven successful as drug targets in the CNS: they constitute the 
target for some of the most efficacious analgesics, and many drugs for depression, anxiety 
and schizophrenia act on GPCRs. Additional GPCRs are emerging as potential targets for 
Parkinson and Alzheimer’s diseases (Lündstrom and Chiu, 2006).  
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In the past decade, mGlu receptors have received much attention due to their strong 
potential as a drug target (Lavreysen and Dautzenberg, 2008). mGlu receptors are of interest 
for the treatment of several neurological and psychiatric disorders, such as depression, 
anxiety, schizophrenia, chronic pain, epilepsy, Alzheimer’s disease and Parkinson’s disease 
(Conn et al., 2009b); Marino and Conn, 2006). mGlu receptors will be discussed in more 
detail in Section 1.2.2.2. 
 
 
1.2. The glutamatergic system in the central nervous system 
 
Glutamate is the major excitatory neurotransmitter in the mammalian brain. 
Approximately 90% of neurons in the brain utilize glutamate as their primary 
neurotransmitter, and 80-90% of the synapses in the brain are glutamatergic (Breitenberg and 
Schüz, 1998). Glutamate is the major mediator of sensory information, motor coordination, 
emotions and cognition (Siegel et al., 2006). The concentration of this neurotransmitter in 
brain gray matter ranges between 10 and 15 µmol per gram of tissue, whereas in the white 
matter it varies between 4 and 6 µmol/g (Siegel et al., 2006). Once synthesized in the pre-
synaptic cytoplasm, glutamate accumulates in synaptic vesicles, by specific transporters, 
termed vesicular glutamate transporters.  
Glutamate participates in many reactions in the brain:  its formation is a step in the 
metabolism of glucose and amino-acids; it is a precursor for GABA in GABAergic neurons 
and for glutamine in glial cells; it is a constituent of proteins and peptides. As a result, 
glutamate is found in all cells of the brain (neuronal and glial cell bodies and their processes), 
both in the cytosol and the mitochondria (Siegel et al., 2006).  
Abnormal glutamate neurotransmission has been related to many neurological 
disorders, including Alzheimer’s disease, Parkinson’s disease, addiction, depression, 
epilepsy, pain, anxiety, and schizophrenia (Rowe et al., 2008). 
 
 
1.2.1. Glutamate receptors 
 
Glutamate binds to and activates two main categories of receptors: ionotropic and 
metabotropic (Figure 5). 
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1.2.1.1 Ionotropic glutamate receptors 
 
Ionotropic glutamate receptors – or ligand-gated ion channels – mediate the vast 
majority of fast synaptic excitatory neurotransmission in the brain (Dingledine et al., 1999) 
and they comprise two functional domains: an extracellular domain which is the 
neurotransmitter binding site and a membrane-crossing domain that forms an ion channel 
(Purves et al., 2004).  
Neurotransmitter binding induces a conformational change in the receptor, increasing 
the probability of channel opening and thus a cation influx. Three classes of ionotropic 
glutamate receptors have been identified and named after the agonist that activates them: N-
methyl-D-aspartate (NMDA) receptors, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic 
acid (AMPA) receptors and kainate (KA) receptors. They all have a different affinity for 
glutamate (Javitt, 2004). Ligand-gated ion channel receptors appear to be a multimeric 
aggregation of different protein subunits. For NMDA receptors, NMDAR1 is the obligatory 
subunit that combines with NMDAR2A-2D subunits to form a gated channel. AMPA 
receptors consist of four different subunits, GluR1-4, all of which can exist in two different 
forms. Kainate receptors are formed by five kainate subunits, GluR5-7 and KA1-2, which can 
undergo alternative splicing and editing (Nakanishi, 1992).  
Due to the fact that ionotropic glutamate receptors are expressed by nearly all types of 
neurons and mediate fast excitatory neurotransmission throughout the brain, direct 
pharmacological manipulation of these receptors is undesired as their inhibition could 
produce widespread disruption of brain function, which could lead to serious side effects 
(Rowe et al., 2008; Swanson et al., 2005). 
 
 
 
 
 
 
 
  
Figure 5: Molecular subtypes of glutamate receptors. Each subtype includes three functionally defined groups (classes) 
of receptor, which are made up of numerous individual subunits that are encoded by different genes. Adapted from 
Siegel et al., 2006 
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1.2.1.2. Metabotropic glutamate receptors 
 
mGlu receptors are, as discussed above (see section 1.1.3.3.), members of the family 
C GPCRs and they are involved in the slower action of glutamate (Lim, 2007). These 
neuromodulatory receptors enable glutamate to modulate cell excitability and synaptic 
transmission through second messenger signalling pathways (Niswender and Conn, 2010). 
 
 
1.2.1.3. The mGlu receptor Family 
 
To date, eight mGlu receptors have been identified and they can be divided in three 
groups (I, II and III) according to their amino acid sequence homology, pharmacology and 
the preferred signal transduction mechanisms they couple to when expressed in vitro (See 
Table 2 for a summary) (Swanson et al., 2005). In addition to these eight mGlu receptors, 
several isoforms of these subtypes are produced by the alternative splicing of their RNAs, 
which generates splice variants in the cytoplasmic C-terminal domain (Litschig et al., 1999; 
Urwyler, 2011).  
 
 
Signal Transduction Mechanisms 
 
Group I receptors (mGlu1/5 receptor) preferentially activate phospholipase Cβ (PLCβ) 
via Gq/G11 proteins. This results in the hydrolysis of phosphatidylinositol (4,5)-bisphosphate 
(PIP2) and the consequent generation of inositol (1,4,5)-trisphosphate (IP3) and sn-1,2-
diacylglycerol (DAG), which initiate a second messenger cascade: IP3 will mobilize Ca2+ 
from intracellular calcium stores, and DAG will increase the activity of membrane-bound 
PKC (Figure 6A). These receptors have been shown to modulate additional signaling 
pathways, including other cascades downstream of Gαq, as well as pathways originating from 
Gαi/o, GαS and other molecules independent of G proteins (Hermans et al., 2001). 
Accordingly, depending on the cell type or neuronal population, group I mGlu receptors are 
capable of inducing the activation of several downstream effectors: phospholipase D, protein 
kinase pathways such as casein kinase 1, cyclin-dependent protein kinase 5, Jun kinase, 
components of the mitogen-activated protein kinase/extracellular receptor kinase 
(MAPK/ERK) pathway, and the mammalian target of rapamycin (MTOR)/p70 S6 kinase 
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pathway (Niswender and Conn, 2010). The last two pathways are presumably important for 
the regulation of synaptic plasticity by group I mGlu receptors (Niswender and Conn, 2010). 
Additionally, when mGlu1a receptors are expressed in several cellular systems they can 
enhance the formation of cAMP and the release of arachidonic acid (Aramori and Nakanishi, 
1992). 
Groups II (mGlu2/3) and III (mGlu4/6/7/8) inhibit adenylyl cyclase activity – which 
will lead to decreases in the cyclic adenosine monophosphate (cAMP) levels – and directly 
regulate ion channels and other downstream signaling partners via Gαi/o proteins (Figure 6B). 
As for group I, group II and III mGlu receptors have been associated with other signaling 
pathways, including activation of MAPK and phosphatidyl inositol 3-kinase PI3 kinase 
pathways (Iacovelli et al., 2002), which shows that the regulation of synaptic transmission by 
these receptors involves different mechanisms (Spooren et al., 2003; Niswender and Conn, 
2010; Wood et al., 2011).  
 
 
 
 
 
 
 
 
  
Figure 6: General signal transduction mechanisms of mGlu receptors. A) 
Group I mGlu receptors signal transduction pathway; B) Group II and III 
mGlu receptors signal transduction pathway (Adapted from Gasparini and 
Spooren, 2007). 
. 
 
A 
 B 
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Pharmacology 
 
The pharmacology of mGlu receptors has been ascertained by studies in both native 
preparations (as brain slice and cultured neurons) and non-neuronal cell lines expressing 
recombinant rat or human mGlu receptors.  
L-glutamate, (1S, 3R)-ACPD, ABH x D-I (agonists) and LY341495 (antagonist) are 
common ligands for the three different mGlu receptor groups (Niswender and Conn, 2010; 
Schoepp et al., 1999), but specific agonists and antagonists for each of the three groups of 
mGlu receptors have been identified. Table 2 summarizes the pharmacological profiles of 
group I, II and III mGlu receptors (full name of the compounds can be found in Appendix 1). 
Besides orthosteric ligands, allosteric ligands – negative (NAM) and positive (PAM) – are 
also presented. The two concepts (orthosteric and allosteric) will be discussed in section 1.3.   
The pharmacology of group III mGlu receptors is not as extensively described as for 
groups I and II, due to the lack of subtype-selective pharmacological tools to study these 
targets (Schoepp et al., 1999). Some of the compounds, of which MPEP and SIB-1893 are 
examples, have shown activity at multiple mGlu receptor subtypes, which require caution 
when interpreting their effect, as it can be arising from different mGlu receptor subtypes.  
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Pharmacodynamic profile Selectivity Compound References
(S )-3,5-DHPG Desai et al ., 1995
Quisqualate Parmentier et al. , 1998
Z -CBQA
E -CBQA
CHPG Doherty et al ., 1997
MCPG and derivatives Niswender and Conn, 2010
LY367385 Clark et al ., 1998
CPCCOEt Litschig et al. , 2000
R214127 Lavreysen et al. , 2003
CTZ Surin et al ., 2007
Bay 36-7620 Carroll et al ., 2001
JNJ 16259685 Lavreysen et al ., 2004
FTIDC Suzuki et al ., 2007
YM 298198 Kohara et al ., 2005
EM-TBPC Malherbe et al ., 2003 a)
SIB-1757
SIB-1893
MPEP Gasparini et al ., 1999
MTEP Cosford et al., 2003
Ro 67-7476
Ro 67-4853
Ro 01-6128
VU60
VU54
VU48
VU34
VU71
DFB
CPPHA
CDPPB de Paulis et al ., 2006
VU29 Chen, 2007
ADX47273 Liu et al ., 2008
DCG-IV Hayashi et al., 1993
(2R ,4R )-APDC Schoepp et al., 1996
1S ,3S- ACPD Pin et al ., 1994
LY354740 Schoepp et al ., 1997
LY379268 Monn et al ., 1999
S -4MeGlu Bräuner-Osborne et al ., 1997a)
2S, 4S -4MG Bräuner-Osborne et al ., 1997a)
NAAG Wroblewska et al ., 1997
L-CBG-I Tsujishima et al ., 1998
L-F2CCG-I Saitoh et al., 1998
LY389795 (?) Monn et al ., 1999
LCCG-I Hayashi et al ., 1992
MGS0028 Nakazato et al , 2000
LY341495 Kingston et al. , 1995
HYDIA Lundström et al. , 2009
LY487379 Schaffhauser et al ., 2003
BINA Galici et al ., 2006
Acetophenone series Trabanco et al ., 2011
MNI-135
MNI-136
MNI-137
RO4988546
RO5488608
Group III AP4 Cartmell et al ., 1998
S -SOP Laurie et al ., 1997
mGluR8 (RS )-PPG Flor et al. , 1998
(+)-ACPT-III Acher et al ., 1997
ACPT-I Acher et al ., 1997
mGluR6 S -Homo-AMPA Ahmadian et al , 1997
mGluR4 S -AP4 Laurie et al ., 1997
Orthosteric antagonist Group III CPPG Kowal et al ., 1998
SIB-1893
MPEP
mGluR4
Littman et al , 1999
Lundström et al ., 2011
Group I
mGluR5
mGluR1
Group I
Hemstapat et al. , 2007
mGluR5
Hemstapat et al ., 2006
Zhang et al. , 2005
mGlu2
mGluR1
mGluR5
Group II
Knoflach et al ., 2001
Mathiesen et al.,  2003
Group III
Group I
Orthosteric agonist
Group II
PAM
Orthosteric agonist
Orthosteric antagonist
PAM
Orthosteric antagonist
NAM
Orthosteric agonist
Varney et al ., 1999
NAM Group II
PAM
Table 2: Pharmacological profile of mGlu receptors. PAM: positive allosteric modulator; NAM: negative allosteric modulator 
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1.2.1.4. Distribution and Functional Roles of mGlu receptors 
 
 
Distribution 
 
mGlu receptors are widely distributed in the CNS, suggesting that these receptors 
have the ability to play a role in numerous functions throughout the brain (Niswender and 
Conn, 2010). They are specifically concentrated at discrete synaptic and extrasynaptic sites in 
neurons and glia in nearly every major brain region and their activation results in diverse 
actions on neuronal excitability and synaptic transmission through the modulation of ion 
channels and other regulatory and signaling proteins (Niswender and Conn, 2010) (Figure 7). 
In general, group I mGlu receptors are localized in the postsynaptic terminal, and, 
when activated, often lead to cell depolarization and increases in neuronal excitability. mGlu1 
receptor immunoreactivity was shown in the caudate putamen, nucleus accumbens and 
globus pallidus (Martin et al., 1992; Baude et al., 1993; Petralia et al., 1997; Testa et al., 
1998; Lavreysen et al., 2004). Moderate expression was found in the substantia nigra pars 
reticulata. Additionally, mGlu1 receptor binding in rat brain was found in the cerebellum, 
thalamus, dentate gyrus and medial central gray. Moderate binding was also found in the 
CA3 of the hippocampus and in the hypothalamus, and, in lower levels, in the basal ganglia 
and cortex (Lavreysen et al., 2004). mGlu5 receptors are widely expressed in the 
hippocampus, caudate/putamen, lateral septum, cortex and olfactory bulb (Shigemoto et al., 
1993; Romano et al., 1995). Astrocytes from the cortex, thalamus, tegmentum, hippocampus 
and striatum have also been found to express mGlu5 (Bradley and Challiss, 2012).  
In contrast to group I, group II and III mGlu receptors are often localized 
presynaptically or in preterminal axons where they inhibit neurotransmitter release (Figure 7). 
This can take place on excitatory, inhibitory and neuromodulatory synapses (Niswender and 
Conn, 2010). 
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Accordingly, group II mGlu receptors (mGlu2 and mGlu3) localize primarily presynaptically 
in the hippocampus, cortex, striatum, thalamus and amygdala (Ohishi et al., 1993a,b). Studies 
of in situ hybridization (Ohishi et al., 1993a,b), immunohistochemistry (Carlton et al., 2001) 
and autoradiography (Schaffhauser et al., 1998) demonstrated the expression of mGlu2/3 in 
the hippocampus, olfactory bulb, neocortical regions, cerebellar Golgi neurons and, with a 
lower level of expression, in thalamic nuclei and striatum (Schaffhauser et al., 2003). 
Astrocytes have also been found to express mGlu3 (Bradley and Challiss, 2012). Group III 
mGlu receptors show an heterogeneous distribution: mGlu4 is highly expressed in cerebellar 
granule cells (Lavreysen and Dautzenberg, 2008) and is present at lower expression levels in 
regions like the hippocampus, amygdala, striatum and olfactory bulb (Lavreysen and 
Dautzenberg, 2008); mGlu6 is found primarily in retinal ON bipolar cells (Nakajima et al., 
1993), but there are indications of low level expression in the hippocampus, limbic, cerebellar 
and cerebral areas (Lavreysen and Dautzenberg, 2008); mGlu7 is broadly distributed in the 
entire brain, and localizes in the active zones of the synapses (Shigemoto et al., 1997; 
Kinoshita et al., 1998); finally, mGlu8 is also widely distributed throughout the brain but it is 
expressed in lower levels than mGlu4 and mGlu7 (Niswender and Conn, 2010); it localizes 
predominantly presynaptically, but also in some postsynaptic locations and in the periphery 
(Lavreysen and Dautzenberg, 2008).  
Figure 7: Scheme of general mGlu receptor localization at the synapse. Niswender and 
Conn, 2010. 
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Functional Roles 
 
The physiological roles of different mGlu receptor subtypes are greatly specific to the 
neuronal population and even subcellular localization (Niswender and Conn, 2010). mGlu 
receptor genetic deletion in mice has helped revealing the potential roles for each receptor.  
High expression of mGlu1 in the hippocampus indicates a potential role in learning and 
memory (Niswender and Conn, 2010). In the same lines, mGlu1 deficiency has been shown 
to lead to a deficit in long-term depression in the cerebellum (Aiba et al., 1994). Lack of 
mGlu1 seems to lead to abnormal levels of regression of climbing fibers from cerebellar 
Purkinje cells, suggesting that mGlu1 plays a critical role in maintaining adequate levels of 
innervations of cerebellar neurons (Levenes et al., 1997). Additionally, it was recently shown 
that several spontaneous mutations which cause spontaneous ataxia in mice are related to the 
ligand-binding domain of mGlu1 (hence, mGlu1 function is suggested to be critical for this 
ataxic phenotype) (Sachs et al., 2007; Niswender and Conn, 2010). mGlu5 is understood to 
have a role in learning and memory, addiction, motor regulation and obesity and it has been 
recently related to the treatment of fragile X syndrome (Niswender and Conn, 2010). Deficits 
in prepulse inhibition (measure of sensorimotor gating that is impaired in schizophrenia 
patients) were seen in mGlu1 and mGlu5 knock-out animals (Brody et al., 2003 and 2004).  
Group II and III mGlu receptors play important roles in the induction of long-term 
depression (LTD), thus reducing the efficacy of transmission (Bellone et al., 2008; Pinheiro 
and Mulle, 2008). Activation of mGlu2/3 decreases synaptic transmission and glutamate 
release in the hippocampus (Macek et al., 1996). mGlu3 seems to have an important role in 
astrocytes: studies with wild-type, mGlu2 and mGlu3 knock-out mice showed that an agonist 
of group II mGlu receptors has neuroprotective effects when NMDA is administered to the 
cells, but that the neuroprotective effect is lost when mGlu3 is absent from astrocytes in the 
cell culture. In the same studies, mGlu2 activation seemed harmful in terms of excitotoxicity 
(Corti et al., 2007). mGlu4 knock-out mice show impairments in cerebellar synaptic plasticity 
and in learning complicated motor tasks (Pekhletski et al., 1996). They also exhibit impaired 
abilities in spatial memory performance (Gerlai et al., 1998). mGlu4 has furthermore been 
shown to modulate GABAA receptor-mediated seizure activity (Snead et al., 2000). mGlu6, 
which is found primarily in the retinal ON bipolar cells, seems to have a fundamental role in 
ON responses to light (Masu et al., 1995; Sugihara et al., 1997). mGlu7 has low affinity for 
glutamate and the deletion of this receptor caused an epileptic phenotype, suggesting that this 
receptor only becomes active when the levels of glutamate are very high, working as a break 
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for overstimulation by glutamate (Niswender and Conn, 2010). Furthermore, knockout 
animals revealed abnormalities in learning tasks. As such, mGlu7 has been implicated in 
amygdala-dependent learning (Masugi et al., 1999). 
The wide presence and range of functions of mGlu receptors throughout the CNS 
renders them important players in CNS disorders. Based on the distribution and physiological 
roles of each mGlu receptor subtype, it is possible to relate them to brain circuits or regions 
implicated in the pathology of CNS-related disorders. Indeed, members of the three groups of 
mGlu receptors have been related to neurological and psychiatric disorders, such as pain, 
schizophrenia, anxiety, depression, epilepsy, fragile X syndrome, cognitive disorders, 
Alzheimer’s and Parkinson’s disease (Gregory et al., 2011).  
Conversely to ionotropic glutamate receptors, whose pharmacological manipulation 
would need to be highly sensitive to avoid disruption of brain function, mGlu receptors 
represent an opportunity for developing drugs that regulate glutamate neurotransmission in an 
indirect and selective manner (Rowe et al., 2008). Due to the wide and heterogeneous 
distribution of these receptors in the CNS, they may act as selective targets for the 
development of new treatment strategies for psychiatric and neurological disorders 
(Niswender and Conn, 2010).  
 
 
1.2.3. mGlu2 receptor receptor in central nervous system diseases – mGlu2 receptor as a 
drug target 
 
The distribution and major functions of group II mGlu receptors in neuronal excitability 
and synaptic transmission, renders the modulation of these receptors a promising strategy for 
the treatment of neurological and neuropsychiatric disorders (Rowe et al., 2008). Preclinical 
and clinical studies strongly suggest that several agonists of this group of receptors have 
potential as a new strategy for the treatment of anxiety disorders and schizophrenia 
(Niswender and Conn, 2010). mGlu2 receptor, particularly, was shown to selectively mediate 
the beneficial effects of group II agonists in rodent models of psychosis (Fell et al., 2008; 
Woolley et al., 2008). The mGlu2 receptor role and its potential for the treatment of 
schizophrenia and anxiety disorders will be discussed in more detail here. 
DCG-IV and (2R, 4R)-APDC were the first selective group II mGlu receptor agonists 
(Schoepp et al., 1999). More recently, systemically active and highly selective agonists of 
group II mGlu receptors have been developed, enabling the investigation of in vitro and in 
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vivo functions of these receptors. The mGlu2/3 receptor agonists LY379268 and LY354740 
cause anxiolytic-like effects and antipsychotic-like activity in animal models used to predict 
efficacy in the treatment of anxiety disorders and schizophrenia (Conn et al., 2009a; Carter et 
al., 2004; Linden et al., 2005) and there are even clinical data supporting the use of mGlu2/3 
agonists for the treatment of anxiety in humans (Grillon et al., 2003). Additionally, LY-
2140023, the prodrug of the mGlu2/3 agonist LY-404039, has been shown to improve 
positive and negative symptoms in schizophrenic patients (Patil et al., 2007; Mezler et al., 
2010). Unlike currently marketed antipsychotic drugs, there were no major adverse effects 
reported for the mGlu2/3 agonist in the clinical studies to date. However, chronic 
administration of group II mGlu receptor agonists induces tolerance in at least one rodent 
model that has been used to predict antipsychotic efficacy (Conn et al., 2009b). 
While these compounds are highly selective for group II mGlu receptors, they do not 
distinguish between mGlu2 and mGlu3, possibly representing a disadvantage since 
preclinical studies with mGlu2 and mGlu3 knockout mice suggest that mGlu2 is likely to be 
the responsible for preclinical efficacy (Spooren et al., 2000). However, novel compounds 
that specifically act on mGlu2 have been identified; they act as so-called positive allosteric 
modulators (PAMs) of mGlu2. Early examples of mGlu2 receptor PAMs include LY487379 
and BINA (Conn et al., 2009a). These compounds have been shown to be highly selective for 
mGlu2 (Conn et al., 2009a) and they have efficacy in animal models that predict 
antipsychotic activity that are very similar to those observed with mGlu2/3 agonists (Galici et 
al., 2005). In recent years there was great progress in the discovery, optimization and clinical 
development of several GPCR subtypes allosteric modulators (Conn et al., 2009 b). Hence, 
the concept of allosteric modulation will now be further discussed.  
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1.3. Allosteric modulation of GPCRs 
 
Allosteric – from the Greek “αλλο” (other) and “στερεο” (object, shape) – modulation 
refers to the regulation of a protein by the binding of a ligand to a site that is topographically 
distinct from its orthosteric – “ορτηο” (correct) – site (the binding site for the natural or 
exogenous/competitive agonists on a receptor) (Urwyler, 2011; Conn et al., 2009b). 
Allosteric modulators induce a change in the three-dimensional receptor conformation, thus 
affecting the affinities and/or efficacies of orthosteric ligands (Urwyler, 2011; Conn et al., 
2009b). Allosteric ligands are, in general, structurally diverse and different from orthosteric 
ligands, particularly from the endogenous natural agonists (Urwyler, 2011).  
Allosteric modulators can be classified according to their effect on the affinity/ efficacy 
of the natural agonist to the receptor: ligands that enhance agonist-induced receptor activity 
are referred to as positive allosteric modulators (PAMs) (or allosteric activators), whereas 
these that decrease agonist activity are termed negative allosteric modulators (NAMs) (or 
allosteric inhibitors); neutral allosteric ligands bind to the allosteric site, but have no effects 
on the responses to the orthosteric agonist. Furthermore, these compounds have one or more 
of the following properties (Figure 8): affinity modulation (the receptor conformational 
change affects the receptor binding pocket, inducing modifications in the association and/or 
dissociation rate of the orthosteric ligand), efficacy modulation (the allosteric modulator 
binding induces a change in the intracellular responses, thus modifying the orthosteric ligand 
signalling capacity) and agonism/inverse agonism (the allosteric modulator affects receptor 
signalling in either a positive (agonism) or negative (inverse agonism) way, irrespective of 
the presence or absence of an orthosteric ligand) (Conn et al., 2009 b).  
 
 
 
 
 
 
 
 
  
Figure 8: Modes of action of allosteric modulators. a) 
Allosteric ligands can affect orthosteric ligand affinity 
(red) and/or efficacy (blue), and even directly perturb 
signalling in their own right (green). b) Effect of three 
different allosteric potentiators on the binding (left) or 
function (right) of an orthosteric agonist: the first (red) 
enhances orthosteric agonist affinity only; the second 
(blue) enhances orthosteric agonist efficacy only; the 
third (green) modestly enhances both affinity and 
efficacy, and also shows allosteric agonism.  
Conn et al., 2009b 
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As mentioned before, GPCRs, including mGlu receptors, have been implicated in 
several human disorders, so they are the target of many therapeutic agents that are currently 
in use. However, synthetic ligands exist for only a fraction of the known GPCRs and the 
production of highly selective compounds suitable as drug leads has proven to be difficult 
(Wood et al., 2011). Several important issues contribute to the difficulty of discovering 
small-molecule selective agonists or antagonists that act on the orthosteric site of some 
GPCRs: orthosteric binding sites are highly conserved for a particular endogenous ligand in 
members of a single GPCR subfamily, which will limit the achievement of subtype 
selectivity; moreover, ligands at orthosteric sites for some GPCRs have other 
physicochemical and pharmacokinetic properties that are incompatible with scaffolds that are 
useful for small-molecule drug discovery (Conn et al., 2009b); also, in case of mGlu 
receptors, ligands that bind the orthosteric binding site are frequently glutamate analogues, 
and for that reason they typically lack the bioavailability and/or CNS penetration desired in a 
probe or drug candidate (Wood et al., 2011). Finally, a main issue with classical GPCR 
agonists is that after repeated dosing they often cause receptor desensitization (Rowe et al., 
2008). Allosteric modulators can, however, overcome some of these obstacles.  
Whereas orthosteric agonists stimulate a receptor independently of its physiological 
state, allosteric ligands that have no agonist activity only exhibit their effects in receptors 
activated by endogenous agonists, being quiescent in the absence of endogenous orthosteric 
ligand. Therefore, these modulators act much more in concert with the temporal and spatial 
organization of endogenous physiological signalling (Conn et al., 2009b), having a lower side 
effect potential and a lower propensity to induce receptor desensitization (Urwyler, 2011). As 
opposed to orthosteric binding sites, allosteric binding sites show a higher sequence 
divergence and hence allosteric modulators can display greater selectivity than orthosteric 
ligands (Urwyler, 2011; Christopoulos, 2002).  Due to the size and number of attachment 
sites of the recognition domain of the endogenous ligands, it is difficult to design low-
molecular-weight synthetic orthosteric ligands that exhibit good bioavailability and/or CNS 
penetration (Urwyler, 2011). 
 There are, however, some negative aspects of allosteric modulators that are worth to 
be mentioned: sequence divergence of allosteric binding sites can result in significant 
differences between species, which will constitute a problem whenever rodent 
receptors/models are used for drug screening or for in vivo trials of an allosteric compound 
characterized in vitro at human receptors; the activity-dependence of PAMs might be seen as 
a disadvantage in neurodegenerative diseases in which the loss of neurons results in 
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decreased availability of the endogenous agonist; the “flat”, non-tractable structure-activity 
relationships that often characterize GPCRs allosteric modulators would be a barrier to the 
improvement of lead molecules; finally, the complexity of the biology of a disease, which is 
often not completely understood, makes it still impossible to find an optimal profile of an 
allosteric drug (Urwyler, 2011). 
 The ubiquity of GPCRs in the CNS renders it important to create a mechanism of 
smoother and selective activation of these receptors and allosteric modulators can provide 
that mechanism. This is considered an emerging area of drug discovery. Whilst GPCR 
ligands likely represent ~50% of all marketed drugs, only two of these, Cinacalcet and 
Maraviroc, are marketed allosteric modulators. This is due to the different approaches needed 
to identify allosteric modulators compared to orthosteric ligands and the relative infancy of 
the field. 
Although allosteric modulators generally display much better features in specificity 
when compared to orthosteric ligands, there are, as mentioned before, a few examples of 
allosteric modulators interacting with multiple receptor subtypes: MPEP and SIB-1893 are 
both mGlu5 NAMs and mGlu4 PAMs; DFB and CPPHA, mGlu5 PAMs, also display weak 
NAM activity on mGlu4; and PHCCC has combined mGlu4 PAM and mGlu1 NAM activity. 
This duality does suggest similarities in allosteric binding sites across different receptors 
(Gregory et al., 2011). For that reason, the characterization of the binding sites of these 
compounds is a fundamental step towards the identification of drugs with increased potency 
and selectivity. Moreover, as more allosteric modulators will likely reach the clinic, it will be 
crucial to understand more about their binding site and mechanism of action. Several 
mutagenesis studies, which have been performed to that aim, have been reported in the 
literature, and will now be further discussed.  
 
 
1.4. Mutational Studies on mGlu receptors 
 
13 years ago, Litschig et al. (1999) reported the first compound acting at and 
inhibiting an mGlu receptor without affecting the binding of the endogenous agonist. Based 
on the sequence alignment of hmGlu1b and hmGlu5a, Litschig et al. identified which amino 
acids could be playing a role in the selectivity of CPCCOEt for hmGlu1b over hmGluR5a. 
Accordingly, they systematically exchanged segments and non-conserved single amino acids 
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between these two subtypes to precisely identify the amino acids mediating the effect of this 
compound (Listchig et al., 1999). Since then, a number of mutagenesis studies on mGlu 
receptors have been published (Table 3) with the purpose of investigating the molecular 
determinants of these receptors. These studies have been performed through the use of 
chimeric receptors, which share segments from different receptor groups/subtypes, point 
mutations on these receptors, and molecular modelling through the alignment of the receptor 
to the TM membranes of the bovine rhodopsin receptor and in silico docking of compounds. 
Mutational studies generate important information on the study of mGlu receptors and 
can be important to reveal how extracellular signals are transmitted into the cells (Listchig et 
al., 1999). Not only have these studies allowed the mapping of the regions of mGlu receptors 
that are critical for modulation of agonist activity (Schaffhauser et al., 2003) they also bring 
insight to the pharmacological profile, site of action and the potential binding mode of novel 
mGlu receptors ligands, allosteric modulators included. Furthermore, the need to identify 
novel selective ligands that are specific for each mGlu receptor subtype to characterize the 
physiological role of individual receptors (Litschig et al., 1999) and to improve selectivity 
and potency – potentially useful for pharmacological modulation of mGlu receptors – makes 
these studies extremely relevant (Pagano et al., 2000; Malherbe et al., 2003). 
In order to predict which amino acids can be playing a role in the interaction 
ligand/receptor, it is essential not only to know the amino acid sequence of the receptor, but 
also its structure, which is inferred using a template from a known GPCR structure. This 
structure can then be used for the docking of allosteric modulators, allowing the 
establishment of a putative model of ligand/receptor interaction. For this purpose, sequence 
alignment and homology modelling have to be performed.  
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Target Ligand EC2 TM3 TM4 TM5 TM6 TM7 References Remarks 
hmGluR1 CPCCOEt       
Thr815 
Litschig et al., 1998  
 
(NAM) 
     
Ala818 
 
hmGluR5 MPEP   Pro655    Ala810 Pagano et al., 2000 
MPEP and CPCCOEt bind to  
 
(NAM) 
 Ser658     
overlapping binding pockets 
rmGluR1 BAY36-7620 (NAM)   
  TM4 – TM7  Carrol et al., 2001 
 
rmGluR1 Ro 01-6128  Ser668  Val757   
Knoflach et al., 2001 
 
 Ro 67-4853  Cys671      
rmGluR5 Ro 67-7476    Pro654    
 (PAMs)    Ser657    
hmGluR2 LY487379   Ser688 Asn735   Schaffhauser et al., 2003  
 (PAM)   Gly689     
rmGluR1 EM-TBPC Asn747   Val757 Trp798 Thr815 
Malherbe et al., 2003a 
 
 (NAM)     Phe801   
 
 
    Tyr805   
rmGluR5 MPEP  Pro654  Leu743 Thr780 Ala809 
Malherbe et al., 2003b 
 
 (NAM)  Tyr658   Trp784    
 
 
    Phe787   
 
 
    Tyr791    
rmGluR1 2,4-dicarboxypyrroles (NAMs) 7TM Micheli et al., 2003  
rmGluR1 CTZ      Thr815 
Surin et al., 2007 Same site as CPCCOEt 
 (NAMs)      Ala818   
rmGluR2/3 MNI-135, MNI-136, MNI-137       
Hemstapat et al., 2007 Asn735: not important for the binding 
 (NAMs)        
of these NAMs 
rmGlu2 RO4988546 His723 Arg635  Leu732 Trp773 Val798 
Lundström et al., 2011 His723 on EC2: 
 RO5488608  Arg636   Phe780   
selectivity of mGluR2 over mGluR3 
 (NAMs)  Phe643      
PAMs/NAMs: Overlapping b.s. 
Tabe 3: Summary of the amino acids identified as important important molecular determinants of mGlu receptors through mutagenesis studies performed on mGlu receptors.  
b.s-binding site; hmGluR (human metabotropic glutamate receptor; rmGluR (rat metabotropic glutamate receptor. 
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Sequence alignment and homology modelling 
 
Homology modelling is used to predict the structure of a protein from its sequence 
(Krieger et al., 2003). It is based on two major observations: the structure of a protein is 
uniquely determined by its amino acid sequence (Epstain et al., 1963), which means that, 
theoretically, the structure of a protein can be obtained once its sequence is known (Krieger et 
al.., 2003); in terms of evolution, the structure is more stable than the associated sequence, so 
that similar sequences still adopt the same structure (Chothia and Lesk, 1986; Sander and 
Schneider, 1991). Homology modelling can be described as a seven step procedure: 1) 
template recognition and initial alignment, 2) alignment correction, 3) backbone generation, 
4) loop modelling, 5) side-chain modelling, 6) model optimization and 7) model validation.  
High-resolution 3-dimensional (3D) structures of proteins provide important 
information on the form and function of those proteins at a molecular level. Not only does 
this information elucidate the aspects of protein structure which underlie physiological 
processes, it is also helpful to examine the interactions of proteins to their ligands and to 
small molecule drugs (Congreve and Marchall, 2010). Palczewski et al. determined for the 
first time the 3D crystal structure of a mammalian GPCR, the visual pigment rhodopsin 
(Figure 9) (Palczewski et al., 2000). The 3D crystal structure of bovine rhodopsin built by 
Palczweski et al. provided a structural template for other GPCRs, enabling the modeling of 
other members of this receptor family. The structure of bovine rhodopsin contains many 
features common to most GPCRs (Palczweski et al., 2000). Furthermore, the molecular size 
of rhodopsin is intermediate among the members of the GPCR family, and the length of its 
7TM helices and extracellular loops are comparable to most of the GPCRs (Palczweski et al., 
2000). Homology models based on rhodopsin structure have been used for the study of 
allosteric interactions at members of class C GPCRs. Even though the sequence similarity 
between class C GPCRs and rhodopsin-like class A GPCRs is low, the allosteric binding site 
of class C receptors share structural features with the orthosteric binding site of the class A 
family (Lundström et al., 2011). 
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Until recently, bovine rhodopsin was the best structure of GPCR receptors and the 
investigation on drug-receptor interaction was limited to models based on homology with this 
structure or from site-directed mutagenesis experiments (Congreve and Marshall, 2010). 
Recently, however, the structures of other GPCRs have been identified (namely β1 (Warne et 
al., 2008) and β2 (Cherezov et al., 2007) adrenergic receptors and adenosine A2a receptor 
(Jaakola et al., 2008)) enabling a wider analysis of structural differences between the 
different receptors.  
 
 
 
  
Figure 9: Three-dimensional representation 
of bovine rhodopsin (Palczewski et al., 2000) 
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1.5. Goal of the project 
 
Janssen Pharmaceutica has an mGlu2 receptor PAM in clinical development for the 
treatment of schizophrenia. In addition, as part of an internal mGlu2 receptor PAM program, 
other potentially important compounds from different chemical series were identified. In 
order to understand the mechanisms through which these compounds might produce their 
effects, it is important to clarify where they bind to the receptor molecule, which receptor 
region is involved and which amino acids are critical for the binding and/or activity.  
In order to identify amino acids potentially important for the interaction between 
PAMs and the mGlu2 receptor, homology modelling and docking of mGlu2 receptor PAMs 
was performed in parallel with experimental site directed mutagenesis. Accordingly, mutant 
mGlu2 receptors were produced. The goal of this study is to evaluate the impact of the 
receptor mutations on the activity of several PAM compounds in order to confirm the role of 
the selected amino acids in the binding and/or activity of PAMs. This work is an important 
contribution to the characterization of the allosteric binding site of mGlu2 receptors. 
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2.1. Materials 
 
The fourteen PAMs tested in this study (Appendix 2 for name and chemical series) 
were synthesized at Janssen Pharmaceutica and dissolved in 100% of dimethyl sulphoxide 
(DMSO). L-glutamate was purchased from Aldrich® Chemistry. The radioligand [3H]-
LY341495 was purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO, 
USA) and Guanosine 5’-(γ-thio)triphosphate [35S]- was purchased from Perkin Elmer® 
(Boston, MA, USA). The monoclonal anti-metabotropic glutamate receptor 2 [mG2Na-s] 
antibody Ab15672 was purchased from Abcam (Cambridge, UK). 
 
 
2.2. Positive allosteric modulators tested 
 
11 compounds used in this study are part of an internal mGlu2 receptor PAM 
program, and were identified by lead optimization of hits originating from high-throughput 
screening through a calcium mobilization assay performed on the mGlu2 receptor. The 
compounds belong to the following chemical classes: 1,4-pyridones, 1,5-pyridones, 
triazolopyridines, isoquinolones and imidazopyridines. 3 reference PAMs were also tested: 
BINA (Galici et al., 2006), the acetophenone LY2605740 (Fell et al., 2011) and LY487379 
(Schaffhauser et al., 2003). Appendix 2 summarizes the chemical series and name of each 
compound used.  
 
 
2.3. Selection of amino acid mutations: sequence alignment and building of an mGlu2 
receptor homology model 
 
The identification and selection of mGlu2 receptor amino acids potentially important 
for PAMs binding, and therefore important targets of mutagenesis studies, was based on 
different approaches. The work described in this section was performed by a co-worker, Gary 
Tresadern (Molecular Informatics).  
Due to the significant difference in the conformation of the EL2, and given the fact 
that this domain has an important role in ligand binding, the mGlu2 receptor structure was 
aligned to both rhodopsin (1GZM) and β2-adrenergic receptor (2RH1) structures, and certain 
conserved motifs between the different receptors were used as constraints to guide the 
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Figure 10: Ribbon 
diagram of the binding 
mode of a reference 
PAM compound in the 
mGlu2 model structure 
built from β2-adrenergic 
template 
alignment. The alignment was performed using Molecular Operating Environment (MOE) 
software with the Protein Align tool (Chemical Computing Group, Canada). 
In order to establish a possible binding mode of mGlu2 receptor PAMs, an mGlu2 
receptor reference PAM was manually docked into the mGlu2 receptor models built from the 
bovine rhodopsin and β2-adrenergic receptor templates, using MOE. Figure 10 shows the 
best ranked docking pose, which was obtained from the mGlu2 receptor model built from the 
β2-adrenergic receptor template. The potentially important amino acids were then selected 
based on 1) their proximity to the ligand (Figure 10) and 2) literature referring amino acids at 
the same position in other mGlu receptors (Figure 11A). Hence, Arg636, Leu639, Phe643, 
Asp725, Leu732, Trp773, Phe776 and Phe780 were selected as candidates for site-directed 
mutagenesis studies.  
Given the fact that most of the PAMs are mGlu2 receptor-selective, the sequences of 
the mGlu2 and mGlu3 receptor were compared in order to identify which amino acids differ 
between the two sequences and, therefore, are potentially important for the selective binding 
of mGlu2 receptor PAM compounds (Figure 11B). The main differences were seen in the 
extracellular portion of TM3, TM4, EL2 and TM5. 
Overall, based on these different approaches (molecular modeling and docking, 
sequence alignment and also literature), 40 amino acids were identified as potentially 
important for the PAM-mGlu2 receptor interaction (Table 4). Mutant mGlu2 receptor cDNA 
constructs were prepared by GeneArt® (Life Technologies) and for this project 21 mGlu2 
receptor mutants (highlighted in blue in Table 4) were further tested. 
 
 
 
 
 
 
 
  
Figure 11: Alignment of mGluR 7TMs. A) Residues highlighted in red boxes have 
been identified as important from literature mutagenesis studies; B) Comparison 
between hmGluR2 and hmGluR3, with highlighted differences 
B 
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WT AA Position Mutation WT codon 
Mutant 
codon 
Name 
Receptor  
region 
 
Ser 688 Leu TCG TTG S688L 
TM4 Litera
tu
re (P
A
M
 1) 
Gly 689 Val GGC GTC G689V 
Asn 735 Asp AAT GAT N735D TM5 
Ser 688 Leu TCG TTG S688L 
TM4 
Gly 689 Val GGC GTC G689V 
Ser 688 Leu TCG TTG S688L 
TM4/5 Gly 689 Val GGC GTC G689V 
Asn 735 Asp AAT GAT N735D 
Arg 636 Ala CGT GCT R636A 
TM3 
D
o
ckin
g 
Leu 639 Ala TTG GCG L639A 
Phe 643 Ala TTC GCC F643A 
Asp 725 Ala GAT GCT D725A 
TM5 
Leu 732 Ala CTG GCG L732A 
Trp 773 Ala TGG GCG W773A 
TM6 Phe 776 Ala TTC GCC F776A 
Phe 780 Ala TTC GCC F780A 
Ser 644 Ala TCT GCT S644A TM3 
m
G
lu
R
2/3
 
co
m
p
a
riso
n 
Val 700 Leu GTC CTC V700L TM4 
His 723 Val CAC GTC H723V EL2 
Ser 644 Ala TCT GCT S644A 
TM3/4/EL2 Val 700 Leu GTC CTC V700L 
His 723 Val CAC GTC H723V 
Arg 635 Ala AGA GCG R635A TM3 Litera
tu
re 
(N
A
M
s
2) 
Met 728 Ala ATG GCG M728A 
TM5 Ser 731 Ala AGC GCC S731A 
Val 736 Ala GTG GCG V736A 
Val 798 Ala GTG GCG V798A TM7 
Ala 681 Phe GCC TTC A681F 
TM4 
m
G
lu
R
2 vs m
G
lu
R
3
 
Ile 693 Met ATT ATG I693M 
Val 695 Ser GTG TCG V695S 
Ala 696 Val GCC GTC A696V 
Gly 706 Arg GGA CGA G706R 
EL2 
Glu 708 Tyr GAG TAC E708Y 
Ala 710 Leu GCC CTC A710L 
Pro 711 Ala CCC GCC P711A 
Val 716 Thr GTG ACG V716T 
Thr 718 Ile ACC ATC T718I 
Ala 726 Ser GCC TCC A726S 
TM5 
Gly 730 Ile GGC ATC G730I 
Ala 733 Thr GCC ACC A733T 
Ala 740 Ile GCC ATC A740I 
Cys 616 Ser TGC TCC C616S 
TM2 
Ile 622 Phe ATC TTC I622F 
Thr 641 Ser ACC TCC T641S 
Ala 642 Ser GCC TCC A642S 
Table 4: mGluR2 mutagenesis constructs. The wild type (WT) and the substituting amino acids are 
indicated, as well as their position and the receptor region where they are located (TM – transmembrane; 
EL – extracellular loop). The first 21 mutations, highlighted in light blue, were tested on this study. 
 
1) Baez et al, 2002; Schaffhauser et al., 2003; Hemstapat et al., 2007; Rowe et al., 2008. 
2) Lündstrom et al., 2011 
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2.4. Chemical transformation of One Shot® Top10 E. coli cells with point-mutated 
human mGlu2 receptors and DNA purification 
 
1 µl of cDNA was added to 50 µl of One ShotTM competent cells (Life Technology) 
and the mixture was incubated 30 min on ice. After that, cells were heat shocked (30 sec at 
42ºC) and rapidly returned on ice for 2 min. 250 µl of S.O.C. medium (InvitrogenTM; 
formulation per liter: 2% tryptone, 0.5% yeast extract, 10 mM sodium chloride, 2.5 mM 
potassium chloride, 10 mM magnesium chloride, 10 mM magnesium sulphate, 20 mM 
glucose) was added and the cells were incubated for 1 h at 37ºC in a rotary shaking incubator 
(InnovaTM 4230, New Brunswick Scientific, Edison, NJ, USA), at 225 rpm. From this, 20 µl 
was spread in a plate and incubated for 18 h at 37ºC. 
In order to prepare a starter culture, one colony was picked from the transformation 
plate to inoculate 5 ml Luria-Bertani (LB) medium containing 100 µg/ml ampicilin. The 
culture was incubated for approximately 6 h at 37 ºC and 300 rpm, in a rotary shaking 
incubator (InnovaTM 4230, New Brunswick Scientific, Edison, NJ, USA). 
For large scale preparation, 500 ml LB medium supplemented with 100 µg/ml 
ampicilin were inoculated with 2.5 ml of the starter culture and incubated overnight at 37ºC 
and 300 rpm (Model G25 Incubator Shaker, New Brunswick Scientific, Edison, NJ, USA). 
The cells were then harvested by centrifugation (Multifuge 3 S-R, Heraeus, 
Buckinghamshire, England). 
 DNA purification from the recombinant E. coli cells was performed using the 
Endofree® Plasmid Maxi/Mega Purification kit (Qiagen GmbH, Hilden, Germany), according 
to manufacturer’s instructions. After purification, the DNA was analyzed through 
sequencing. 
 
 
2.5. Cell culture 
 
CHO-K1 cells (ATCC: CCL-61) were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS; 
HyClone®, Thermo Scientific, Cramlington, UK) and 2% (v/v) Solution A. Solution A 
consists of Penicillin G (Serva, Bioconnect, Huissen, The Netherlands) 5.10e6 IU/L, 
Streptomycin sulphate (Serva) 5 g/L, Pyruvic acid (Sigma) 5.5 g/L and L-Glutamine (Sigma, 
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St. Louis, MO, USA) 14.6 g/L. Cells were kept at 37ºC in a humidified atmosphere with 5% 
CO2. 
 
 
2.6. Transient transfection of human mGlu2 receptor cDNA into CHO-K1 cells 
 
CHO-K1 cells were seeded in 145 cm2 Petri dishes (NuncTM, Roskilde, Denmark) at a 
seeding density of 20000 cells/cm2 in DMEM supplemented with 10% heat-inactivated FBS 
and 2% Solution A. 24h later, when a confluence of 50-70% was reached, human mGlu2 
receptor (hmGluR2) cDNA, WT and mutated (Table 4, mutation 1 – 21) was transiently 
transfected into CHO-K1 cells using Lipofectamine® (InvitrogenTM, Life TechnologiesTM), 
and the recombinant cell lines were incubated overnight in the same medium, at 37ºC and in 
an atmosphere of 5% CO2. One plate was used for transfection with the plasmid encoding the 
Enhanced Green Fluorescent Protein (EGFP-N1) to be used as a control of the transfection 
efficiency. 20-24 h after the transfection, the medium was replaced by fresh medium, and 20-
24 h after the medium replacement butyrate (final concentration of 5 mM) was added to each 
plate. The transfection efficiency was qualitatively evaluated at this point through the 
visualization of the cells transfected with EGFP-N1, using a fluorescence microscope 
(Axiovert 135, Zeiss, N.V., S.A.). 20-24h after the addition of butyrate, the plates with 
recombinant cells were washed twice with ice-cold phosphate-buffered saline (PBS) and 
stored at -80 ºC, or used readily for membrane preparation. 
 
 
2.7. Membrane preparation 
 
Confluent plates with transfected CHO-K1 cells expressing the wild-type or mutant 
hmGlu2 receptors were harvested with a cell scraper and resuspended in ice-cold 50 mM 
Tris-HCl buffer, pH 7.4. The cell suspension was, from this moment on, always kept on ice. 
The cell suspension was centrifuged for 10 min at 16000 rpm in a Sorvall 5C PLUS SS34 
centrifuge at 4ºC. The resulting cell pellet was resuspended and homogenized in ice-cold 5 
mM Tris-HCl, pH 7.4, using an Ultra Turrax homogenizer (IKA TE5) at 24000 rpm. 
Additional 5 mM Tris-HCl was added to the homogenate and it was centrifuged again for 20 
min at 18000 rpm in a Sorvall RC 5B/RC 28S centrifuge at 4ºC. The final pellet was 
resuspended and homogenized in 50 mM Tris-HCl using the Ultra Turrax homogenizer, and 
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the membrane suspension was aliquoted in cryovials and frozen at -80ºC. The protein 
concentration was measured using the Bradford method (Bio-Rad Protein Assay, Bio-Rad 
Laboratories, Munich, Germany) using bovine serum albumin (Sigma, St. Louis, MO, USA) 
as standard. 
 
 
2.8. Western Blot analysis 
 
hmGlu2 receptor membranes were thawed and homogenized using the Ultra Turrax 
homogenizer. 200 μl of membrane suspension was transferred to a tube and 400 μl of RIPA 
buffer (150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 
50 mM Tris, pH 8.0, Sigma) complemented with phosphatase and protease inhibitors (Roche) 
was added. The lysate was incubated 30 min on ice, and centrifuged at 14000 rpm (20 min, 
4ºC). The supernatant fraction was recovered to a fresh tube and the protein concentration 
was determined by BCATM Protein Assay (Sigma-Aldrich). 
3 μg of protein was loaded on NuPAGE® Novex® Tris-Acetate 4-12% Bis-Tris Gel 
(Life Technologies). The electrophoresis ran initially at 100 V, after which the voltage was 
increased to 170-200 V. The proteins on the gel were blotted for 8 min on a nitrocellulose 
membrane through a dry blotting system (iBlot, Life Technologies). Membranes were 
blocked for 1h at RT with Non-Fat Dry Milk (NFDM) (Santa Cruz, Technology) (5% w/v) 
diluted in Tris buffer (10mM Tris pH8.0, 150mM NaCl and 0.05% v/v Tween 20) 
(Amersham Biosciences, GE Healthcare, Little Chalfond Buckinghamshire, UK) (TBS-T), 
after which they were washed three times in TBS-T. The membranes were then incubated 
with the primary antibody (anti-metabotropic glutamate receptor 2 antibody; final 
concentration 0.75 μg/ml) diluted in 5% NFDM in TBS-T, overnight at 4ºC, with gentle 
agitation. Primary antibodies were detected through the HRP-linked secondary antibody 
(1:10000 in TBS-T, Amersham Biosciences) via SuperSignal® West Dura Extended Duration 
Substrate (Pierce, Thermoscientific). Signals were captured and quantified by 
chemiluminescence (G-box Syngene, Syngene). 
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2.9. Radioligand binding assay – [3H]-LY341495 binding 
 
Theoretical background 
 
The binding of a ligand to its receptor is the first and indispensable step in the chain 
of reactions that will lead to a pharmacological effect (de Jong et al., 2005). Therefore, the 
process of ligand binding can be measured to investigate receptor molecules and the binding 
properties of a given compound acting on the receptor (Vauquelin and von Mentzer, 2007).  
Radioligand binding assays are based on the ability of an analyte (unlabelled ligand) 
to displace a radioactively labelled ligand (radioligand) that binds to the receptor of interest. 
The radioactively labelled ligand must be appropriate to be used in a radioligand binding 
assay, and therefore it must obey several criteria: it should exhibit high affinity and 
selectivity to the receptor that is being studied; it should display a high specific activity 
towards the receptor; and it should be radiochemically pure, stable and resistant to enzymatic 
degradation (de Jong et al., 2005; Vauquelin and von Mentzer, 2007). Tritium (3H) and 
iodine (125I) are the most commonly used isotopes for ligand radio labelling: tritium exhibits a 
longer half-life than iodine (12.3 years over 60 days, respectively), which enables longer 
periods of storage, but since it has a lower specific radioactivity than iodine (29 Ci/mmol 
over 2125 Ci/mmol, respectively) it is only suitable when the tissue under study contains 
sufficient amounts of the receptor of interest (Vauquelin and von Mentzer, 2007). 
Radioligand binding studies involve three important concepts: specific binding (the 
binding to the receptor of interest), non-specific binding (the observed binding in the presence 
of an appropriate excess of unlabeled competitor ligand – corresponds to binding to filters, 
absorption to the tissue, dissolution in membrane lipids) and total binding (the combination 
of specific and non-specific binding). Specific binding is determined by subtracting the non-
specific binding from the total binding. Receptor-bound radioligand is separated from free 
through filtration, centrifugation or suction, followed by the measurement of the remaining 
radioactivity. 
Radioligand binding studies can be performed through different experimental 
approaches. Saturation binding experiments are performed using a constant amount of target 
receptor and increasing concentrations of radioligand. From these experiments the amount of 
the receptor of interest can be determined. Furthermore, the KD of a radioligand, i.e. the 
concentration of radioligand needed to bind 50% of the receptors and hence a measure of the 
affinity of the radioligand for the receptor, can also be determined. Competition binding 
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experiments use constant amounts of protein and radioligand, but increasing concentrations 
of an unlabeled ligand to be tested. These experiments provide information on the affinity of 
that ligand to a receptor. Finally, kinetic experiments enable the determination of the rate 
constants for radioligand association and dissociation. 
 
 
Procedure 
 
In this study, both saturation and competition binding experiments were performed. 
hmGluR2-CHO-K1 membranes were thawed and homogenized using the Ultra Turrax 
homogenizer and the protein concentration was measured using the Bradford Method (Bio-
Rad Protein Assay, Bio-Rad Laboratories, Munich, Germany). Membranes were diluted in 
ice-cold binding buffer containing 50 mM Tris-HCl, pH 7.4, 10 mM MgCl2 and 2 mM CaCl2. 
The reaction mixture contained 10 µg of membrane protein and 3 nM of [3H]-LY341495 in a 
total volume of 500 µl. In order to measure the non-specific binding, 1 mM glutamate was 
used. The reaction mixture was incubated for 60 min at room temperature (RT). The 
incubation was stopped with a filtration step using Unifilter-96 GF/B filter plates in a 96-well 
PerkinElmer filtermate harvester, and the plates were dried overnight at RT. The remaining 
radioactivity was measured in a Microplate scintillation and luminescence counter (Packard). 
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2.10. [35S]GTPγS binding assay 
 
Theoretical background 
 
 This functional assay measures the level of G protein activation that follows agonist 
occupation of a GPCR. The activation of a GPCR involves the exchange of GDP for GTP at 
the Gα-subunit of G-protein heterotrimers. This event is followed by the dissociation of the 
G-protein α-subunit from the βγ complex, which will then both elicit downstream signal 
transduction events. The Gα subunit possesses an endogenous GTPase activity, which will 
cause the GTP hydrolysis into GDP, an event enabling the reassembly of Gα and Gβγ 
subunits and the termination of the receptor activity, providing a mechanism to restrain the 
duration of the signal (Figure 2.1a). 35S-labeled guanosine 5′-O-(γ-thio)triphosphate 
([35S]GTPγS) is an analogue of GTP that is also able to bind to the α-subunit, but is resistant 
to its GTPase activity; because this non-hydrolysable form of GTP remains bound for a 
sufficient period of time, it allows counting of the amount of [35S] label incorporated 
(Lazareno, 1997; Kowal et al., 1998) (Figure 2.1 b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 12: a) Once an agonist binds to a receptor, GDP is replaced by 
GTP on the Gα subunit of the G protein; Gα subunit and Gβγ complex 
both activate cellular effectors; the GTPase activity of α subunit 
hydrolyses GTP to GDP, the three subunits reassemble and the receptor 
is turned off. b) When [35S]GTPγS is present, its exchange for GDP also 
occurs, but the GTPase activity of the Gα subunit is unable to hydrolyse 
[35S]GTPγS, which accumulates. Harrison and Traynor, 2003 
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This functional assay measures an early receptor-mediated functional response – 
important to avoid amplification that can occur when analyzing parameters further 
downstream of the receptor – and it enables the determination of basic pharmacological 
parameters of compounds acting at GPCRs, such as potency, efficacy and antagonist affinity 
(Harrison and Traynor, 2003).  
 
 
Procedure 
 
hmGluR2-CHO-K1 membranes were thawed on ice and homogenized using the Ultra 
Turrax homogenizer and the protein concentration was measured using the Bradford method 
Bio-Rad Protein Assay kit. The membranes were diluted in assay buffer (pH 7.4 solution of 
10 mM HEPES acid and 10 mM HEPES, containing 100 mM NaCl, 3 mM MgCl2, 10 µM 
GDP and 14.3 µg/ml saponin). 
The assay mixture (final total volume of 200 µl) contained 18 µl of assay buffer, 2 µl 
of test compound (at 10-fold final concentration), 20 µl of glutamate and 10 µg of membrane 
protein, after the addition of which a pre-incubation step of 30 min at 30 ºC was performed. 
Finally, 0.1 nM [35S] GTPγS was added and the assay mixture was incubated for another 30 
min at 30 ºC. The reaction was stopped through filtration using Unifilter-96 GF/B filter plates 
(PerkinElmer Life Sciences, Boston, MA) in a 96-well PerkinElmer filtermate harvester, in 
order to remove the unbound [35S] GTPγS. The filters were washed 3 times with ice-cold 10 
mM NaH2PO4/ 10 mM Na2HPO4 buffer, pH 7.4, and dried overnight at room temperature. 40 
μl of MicroscintTMO (Perkin Elmer, MA, USA) was added to each well, covered with a plate 
sealer, and 30 min later the remaining radioactivity was counted in a Microplate scintillation 
and luminescence counter (Packard). When testing compounds for their PAM effect, the 
GTPγS assay was performed using 4 μM glutamate (corresponding to the EC20 of glutamate) 
as agonist. 
 
 
2.11. Data analysis 
 
Data analysis was performed using GraphPad Prism version 4.02 for Windows 
(GraphPad Software, San Diego, USA). Concentration-response curves were fitted using 
non-linear regression analysis fitting the equation: Y=Bottom + (Top-
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Bottom)/(1+10^((LogEC50-X)*HillSlope)). Saturation binding experiments were analyzed 
using a non-linear regression analysis.  
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3.1. Expression of WT and mutant mGlu2 receptors in CHO-K1 cells 
 
Once purified, DNA from WT and mutant hmGlu2 receptors was analyzed through 
sequencing, which confirmed the correct sequence for all cases.  
The efficiency of transient transfections into CHO-K1 was qualitatively evaluated 
through EGFP-N1 expression and consequent fluorescence each time a new transfection was 
performed, which always revealed an efficiency of about 30-35% (Figure 13). 
 
 
 
 
 
 
In order to assess the expression of WT and mutated receptors in membranes of CHO 
transfected cells, Western blots were performed using an antibody that recognizes a 47 amino 
acid sequence of the C-terminal tail of mGlu2. Non-transfected CHO-K1 (referred to as CHO 
WT), CHO-K1 stably transfected with WT hmGlu2 (referred to as CHO mGlu2 Stable) and 
CHO-K1 transiently transfected with WT hmGlu2 (referred to as CHO mGlu2 Trans.) were 
used as controls. Except for the non-transfected cells, for each sample, two main bands were 
detected: a immunoreactive band running at ~ 100 kDa corresponding to the monomeric form 
of mGlu2 and a band running at ~200 kda corresponding to the homodimer. The immunoblot 
analysis (Figure 14) revealed the differences in expression levels for the different samples, 
but overall confirms the expression of each mGlu2 receptor (WT and mutant) in CHO-K1 
cells. Mutant W773A (#11) displays a rather low expression level of the mGlu2 homodimer. 
 
 
 
Figure 13: Visualization of transient transfection efficiency in CHO-K1 cells, through expression of EGFP-N1; 
this procedure was repeated each time a transfection was performed; the displayed images are representative 
examples of this evaluation, and correspond to the transfection of A: WT hmGlu2, B: Mutation G689V and C: 
Mutation R636A 
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To further confirm the expression of mGlu2 in CHO-K1 cells, and to observe whether 
any of the mutations affected the orthosteric binding site or the receptor conformation needed 
for binding of orthosteric molecules like glutamate, radioligand binding studies were 
performed using the orthosteric mGlu2/3 receptor antagonist [3H]-LY341495.  
All mutated receptors showed similar specific [3H]-LY341495 binding (in the range 
of 90%), confirming that the orthosteric site had remained intact in the mutated receptor 
forms. Furthermore, glutamate was able to displace [3H]-LY341495 in a concentration-
dependent manner, both from the receptor stably expressed in CHO-K1 cells and from 
transiently transfected WT or mutant receptors (Figure 15), confirming that mutant receptors 
were still able to bind glutamate.   
Figure 14: Western blot analysis on mGlu2 WT and mutant receptors to illustrate the expression of the receptors 
in CHO-K1 cells after stable (for WT hmGlu2) or transient transfection (for WT and mutant hmGlu2). Mutants 
are indicated with the corresponding mutation number (See Table 6, Methods section). As expected, the monomer 
(~100 kDa) and dimer (~200 kDa) are observed and this staining pattern is the same for WT and mutant mGlu2. 
Actin (antibody diluted 1:2000 in TBS-T) is presented as a loading control. Molecular weight markers are 
indicated in kDa. A representative immunoblot of 2 independent experiments is shown. 
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Figure 15A does show that, for different mGlu2 constructs, the absolute values of 
total binding vary, which is likely due to differences in receptor expression levels. Namely 
mutation W773A (#11) shows a prominent decrease in total binding, consistent with the 
results obtained in Western blot analysis. pIC50 values for glutamate binding inhibition were 
similar for all receptors (pIC50 of 5 corresponding to an IC50 of 10 μM) (Table 5) (n=1 or 
n=2). 
 
  
Figure 15: Displacement of [3H]-LY341495 binding from hmGlu2-WT (stably and transiently transfected) and hmGlu2 
mutants by glutamate. The affinity of glutamate is not altered by any of the mutations (see Table 5 for all the results). A) 
Total binding results are presented as counts per minute (cpm); data presented as mean±S.D. of one experiment performed 
in triplicate. B) Results are presented as percentage of specific binding, i.e. total binding (binding in the absence of 
glutamate; corresponds to 100%) minus non-specific binding (binding in the presence of 1 mM glutamate)); data is 
presented as mean±S.D. of one experiment performed in triplicate. 
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It is of note that the differences in expression level were also evaluated with a modest 
set of saturation experiments using [3H]-LY341495; as can be seen from Table 6 and Figure 
16, for the tested mutations (S688L (#1), G689V (#2), R636A (#6) and L639A (#7)), these 
studies furthermore confirmed that expression levels in the transiently transfected cell 
membranes could vary and that expression levels were lower than in the stably transfected 
cells. Nevertheless, the KD of [
3H]-LY341495 was unchanged, indicating that also orthosteric 
antagonists bind with similar affinity to the orthosteric binding site.  
Receptor Region Mutation pIC50 glutamate 
--- Stable WT 4.9 ± 0.10 
--- Transient WT 4.9 ± 0.07 
T
M
3 
R635A (#18) 4.9 
R636A (#6) 4.8 
L639A (#7) 4.9 
F643A (#8) 4.8 ± 0.06 
S644A (#14) 4.7 
T
M
4 
S688L (#1) 4.7 ± 0.06 
G689V (#2) 4.7 
S688L/G689V (#4) 4.7 
S688L/G689V/N735D (#5) 4.7 
V700L (#15) 4.9 
S644A/V700L/H723V (#17) 4.8 
E
L
2/
T
M
 5
 
H723V (#16) 4.6 
D725A (#9) 5.0 
M728A (#19) 4.9 
S731A (#20) 5.0 
L732A (#10) 4.9 ± 0.06 
N735D (#3) 4.8 
V736A (#21) 4.9 
T
M
 6
 W773A (#11) 4.9 ± 0.12 
F776A (#12) 4.8 
F780A (#13) 4.9 
Table 5: Summary of pIC50 values for displacement of [3H]-LY341495 binding from hmGlu2-WT (stably 
and transiently transfected) and hmGlu2 mutants by glutamate. Mutations are sorted by receptor region. For 
WT, data is presented as mean±SD of at least 3 concentration-response measurements performed in triplicate; 
for mutants S688L (#1), F643A (#8), L732A (#10), W773A (#11) and H723V (#16) data is presented as 
mean±SD of at least 2 concentration-response measurements performed in triplicate; for the restant mutations, 
the results of one concentration-response measurement performed in triplicate are presented.  
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Figure 16: Saturation binding curves and correspondent Scatchard plots of [3H]-LY341495 binding to 
WT (stably and transiently transfected) and mutant mGlu2 receptors (S688L, G689V, R636A and 
L639SA) expressed in CHO-K1 membranes. Data are presented as nanomolar specifically bound. 
Data points were determined in triplicate (n=1).  
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3.2. Glutamate potency for WT and mutated mGlu2 receptors 
 
In order to further verify the effect of the mutations on the glutamate binding pocket 
and on the signalling mechanisms of the receptor, the potency of glutamate in WT and mutant 
hmGlu2 was assessed through functional studies using a [35S]GTPγS assay.  
pEC50 values were calculated from concentration-response curves of glutamate in 
membranes of CHO-K1 cells expressing the WT (stably and transiently transfected) and the 
mutated hmGlu2 receptors (Figure 16, Table 6). On the WT receptor, glutamate typically 
exerts effects with a pEC50 of ~ 5.05 and EC50 values of ~ 9 μM
1.  
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
1 Data from Janssen’s central data warehouse. 
 KD (nM) Bmax (fmol/mg of protein) 
mGlu2 Stable WT 0.87 6480 
mGlu2 Trans. WT 0.72 6900 
S688L (#1) 0.67 3661 
G689V (#2) 0.78 4379 
R636A (#6) 0.88 3197 
L639A (#7) 0.76 3748 
Figure 16: Representative graph of the effect 
of a set of mGlu2 receptor mutations on 
glutamate-induced [35S]GTPγS binding. 
Data are from one experiment where 
glutamate concentration-response curves 
were determined on membranes from CHO-
K1 cells expressing WT (stably and 
transiently transfected) and 5 mutant 
receptors (transiently transfected) in parallel. 
Results are expressed as a percentage of the 
response to 1 mM glutamate. 
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Table 6: Equilibrium binding constants of [3H]-LY341495 binding to CHO membranes 
expressing WT and mutant mGlu2 receptors (n=1).  
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Receptor Region Mutation pEC50 Response amplitude (%) 
   
--- Stable WT 5.0 ± 0.12 637% ± 122% 
 
  
--- Transient WT 5.3 ± 0.15 261% ± 73% 
  
T
M
3 
R635A (#18) 4.9 ± 0.24 217% ± 49% 
  
R636A (#6) 5.2 ± 0.15 196% ± 22% 
  
L639A (#7) 5.2 ± 0.12 280% ± 37% 
  
F643A (#8) 4.9 ± 0.22  222% ± 60% 
 
  
S644A (#14) 5.2 ± 0.12  237% ± 78% 
  
T
M
4 
S688L (#1) 5.2 ± 0.15 232% ± 64% 
  
G689V (#2) 5.2 ± 0.22 237% ± 89% 
  
S688L/G689V (#4) 5.2 ± 0.18 249% ± 76% 
  
S688L/G689V/N735D (#5) 5.3 ± 0.27 235% ± 69% 
  
V700L (#15) 5.2 ± 0.14 278% ± 32% 
 
  
S644A/V700L/H723V (#17) 5.0 ± 0.19 313% ± 55% 
  
E
L
2/
T
M
 5
 
H723V (#16) 5.1 ± 0.13 282% ± 58% 
  
D725A (#9) 5.3 ± 0.14 250% ± 19% 
  
M728A (#19) 5.1 ± 0.12 274% ± 132% 
  
S731A (#20) 5.2 ± 0.25 331% ± 61% 
  
L732A (#10) 5.4 ± 0.18 346% ± 103% 
  
N735D (#3) 5.1 ± 0.04 253% ± 69% 
 
  
V736A (#21) 5.1 ± 0.07 248% ± 19% 
  
T
M
 6
 W773A (#11) 5.0 ± 0.48 171% ± 30% 
  
F776A (#12) 5.3 ± 0.12 326% ± 82% 
   F780A (#13) 5.2 ± 0.13 303% ± 43% 
 
 
As shown in Figure 16 and Table 7, mutated receptors elicited concentration-response 
curves for glutamate with potencies that were similar to those of the WT receptor. The 
amplitude of the response to glutamate – i.e. the ratio between the response obtained under 
basal conditions (only using assay buffer), corresponding to 100%, and the response obtained 
with 1 mM glutamate – was considerably lower in transiently transfected CHO-K1 cells.  
 
  
Table 7: Effect of mGlu2 receptor mutations on glutamate-induced [35S]GTPγS binding. Concentration-response curves were 
determined in the presence of increasing concentrations of glutamate on membranes from CHO-K1 cells expressing WT (stably and 
transiently transfected) and mutant receptors (transiently transfected). Mean pEC50±SD and mean percentage of glutamate stimulation 
(defined as the ratio between the response obtained under basal conditions i.e. only using assay buffer, corresponding to 100%, and the 
response obtained with 1 mM glutamate) ±SD are given. Data presented was calculated from at least 3 concentration-response 
measurements performed in triplicate; except for mutants R636A (#6) and M728A (#19) for which data was calculated from 2 
concentration-response measurements performed in triplicate. Mutations are again sorted by receptor region. 
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 3.3. Effect of mGlu2 mutations on the activity of positive allosteric modulators 
 
[35S]GTPγS binding was used to assess the effect of each mutation on the activity of 
14 mGlu2 receptor PAMs. The results of this analysis are summarized and presented as 
follows. 
From each chemical series, one representative compound is chosen to be presented 
graphically: JNJ-40068782 (1,4-pyridones), JNJ-35814376 (1,5-pyridones), JNJ-42153605 
(triazolopyridines) JNJ-40297036 (isoquinolones) and JNJ-41482012 (imidazopyridines). 
Results for the reference compounds JNJ-52149617 (LY2605740, acetophenone, Fell et al., 
2011), JNJ-35815013 (BINA, Galici et al., 2006) and JNJ-35814090 (LY487379, 
Schaffhauser et al., 2003) are also visualized in the graphs. Mutations are again sorted by 
receptor region.  Hence, the results presented graphically represent a summary of the effects 
for a particular chemical structure, for a given receptor region. The results for the complete 
set of compounds are displayed in Table 8. This complete set of data will be discussed 
elsewhere (Section 4.3), and particular focus will be put on dissimilarities between 
compounds in a particular chemical series. 
The [35S]GTPγS experiments were set up as follows. In a first step, to preliminary 
assess the effect of each mutation on the PAM activity, only two concentrations of PAM were 
tested: a PAM concentration that produces 50% stimulation (EC50) and a concentration that 
produces a maximal stimulation (EC100)
2. This two-concentration screening was considered 
necessary, as testing only the highest concentration (EC100) could mask the true effect of the 
compound: as displayed in Figure 17, the maximal response (Emax) of the compound on the 
mutated receptor is the same as for the WT receptor, but the curve has shifted to the right. 
Although the Emax – which would be detected in case of using the compound’s EC100 – is the 
same, which would indicate that the compound has similar activity in WT and mutated 
receptor, the potency is lower.  
 
 
 
 
 
 
                                                          
2
 These values were taken from previous experiments for which data is stored in Janssen’s central database. 
A4 - 06094 - Ana Farinha - thesis binnenwerk.indd   63 28/06/2012   9:58:44
 
 
64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As mentioned in the Methods section, PAMs were tested using 4 μM glutamate 
(correspondent to the EC20). Per mutation, for each PAM compound, [
35S]GTPγS binding in 
the presence of the PAM was calculated as a percentage of the response to 1 mM glutamate 
(no PAM added). Effects lower than 75% of the effect seen on the transiently transfected WT 
receptor were considered significantly different, and hence these mutations were selected for 
further analysis.  
Figure 18 displays the results obtained in the screening test for the representative 
compounds of each chemical series, comparing the effect of the different compounds 
between WT and mutant mGlu2. For a detailed overview table, showing the exact values 
obtained for the complete set of compounds and mutations, we refer to Appendix 3. 
 
  
Figure 17: Effect of increasing concentrations of BINA (JNJ 
35815013), a reference PAM, on glutamate-induced 
[35S]GTPγS binding and the importance of performing a 
screening assay with EC50 and EC100: for EC100 the 
receptor with the mutation G689V exhibits similar effects as 
the WT (transiently transfected into CHO-K1); however, 
since the compound is less potent, this similarity is no 
longer observed with lower concentrations (e.g. EC50).   
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Figure 18: Screening of 8 mGlu2 receptor PAMs, representative of the 8 different chemical classes tested in this 
study, using the      EC50 and      EC100 on WT (stably transfected “Stable WT” and transiently transfected “Trans. 
WT”) and mutated hmGlu2 (mutations #6 to #21). For the mutations S688L (#1), G689V (#2), N735D (#3), 
S688L/G689V (#4) and S688L/G689V/N735D (#5) this screening was not performed. 75% of Trans. WT (“75% of 
T. WT”) response is also displayed. Mutations for which the compound effect was lower than “75% of T. WT”, for 
any of the concentrations (i.e. the mutations for which bars appear below the red dashed line) were further tested. 
See Appendix 3 for a complete summary of results. 
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As shown in Figure 18, this screening assay enabled an early exclusion of several 
mutations based on the criteria mentioned above: for all compounds, mutations R636A (#6), 
D725A (#9), V700L (#15), M728A (#19) and V736A (#21) showed an effect higher than 
75% of the effect on WT, for both EC50 and EC100 of all compounds, and were therefore 
considered to have no effect on the activity of any of the compounds tested.  
For the mutations showing an effect lower than 75% of the effect in WT for a given 
compound, a concentration-response curve of that compound on membranes of CHO-K1 
cells expressing that mutation was generated. From this, potency (EC50) and relative efficacy 
(Emax) values were calculated for the 14 PAMs on mGlu2 WT versus mutant receptors. 
Figures 19-22 graphically display the results obtained with the 8 representative compounds 
on the mutations localized in the different receptor regions. The potency (EC50) and relative 
Emax calculated from the concentration-response curves for the 14 compounds on WT and 
mutant receptors are presented in Table 8. In this table, the difference in compound potency 
is also calculated as a ratio of EC50 between WT and mutant mGlu2 (for a more detailed table 
with additional information on individual experiments, see Appendix 4). 
Figure 19 shows the results obtained from the concentration-dependent enhancement 
of glutamate-induced [35S]GTPγS binding by the 8 representative compounds on WT mGlu2 
and on mGlu2 with mutations localized in transmembrane 3. As seen in Figure 18, all the 
mutations seem to affect the activity of the tested compounds. Mutation F643A (#8) shows 
the most prominent results, as it not only causes a decrease in potency (right-ward shift of the 
concentration-response curve) but also a decrease in Emax. EC50 values were increased by 6.4 
to 157-fold for the different compounds tested (Table 8). Mutation L639A (#7) also affects 
the activity of all compounds, albeit to a lower extent compared to mutation F643A (#8) (1.3 
to 15-fold increase in EC50, as shown in Table 8). Mutation S644A (#14) decreased the 
potency of all the compounds tested, with the exception of JNJ-39226421 (Figure 19, Table 
8). Mutation R635A (#18) showed a decrease in potency of JNJ-35814376 (Figure 19E) and 
JNJ-40068782 (Figure 19H), but an increased maximal response. Additionally, this mutation 
caused a 5.6-fold increase in the potency of JNJ-35815013. 
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Figure 19: Effect of PAMs on glutamate-induced [35S]GTPγS binding in WT mGlu2 and mGlu2 with mutations located in 
transmembrane 3 (TM3). A to H, concentration-dependent enhancement of 4 μM glutamate-induced [35S]GTPγS binding 
by 8 PAMs, representative of the 8 chemical classes used in this study. Results are expressed as a percentage of the 
response to 1 mM glutamate, and refer to one experiment performed in triplicate. See Table 7 for a complete summary of 
results obtained for 14 PAMs on 21 receptor mutants. 
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Figure 20: Effect of PAMs on glutamate-induced [35S]GTPγS binding in WT mGlu2 and mGlu2 with mutations located in 
transmembrane 4 (TM4). A to H, concentration-dependent enhancement of 4 μM glutamate-induced [35S]GTPγS binding by 8 
PAMs, representative of the 8 chemical classes used in this study. Results are expressed as a percentage of the response to 1 mM 
glutamate, and refer to one experiment performed in triplicate. See Table 7 for a complete summary of results obtained for 14 
PAMs on 21 receptor mutants. 
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Figure 21: Effect of PAMs on glutamate-induced [35S]GTPγS binding in WT mGlu2 and mGlu2 with mutations located in 
extracellular loop 2 and transmembrane 5 (EL2/TM5). A to H, concentration-dependent enhancement of 4 μM 
glutamate-induced [35S]GTPγS binding by 8 PAMs, representative of the 8 chemical classes used in this study. Results are 
expressed as a percentage of the response to 1 mM glutamate, and refer to one experiment performed in triplicate. See Table 
7 for a complete summary of results obtained for 14 PAMs on 21 receptor mutants. 
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Figure 21: Effect of PAMs on glutamate-induced [35S]GTPγS binding in WT mGlu2 and mGlu2 with mutations located in 
extracellular loop 2 and transmembrane 5 (EL2/TM5). A to H, concentration-dependent enhancement of 4 μM 
glutamate-induced [35S]GTPγS binding by 8 PAMs, representative of the 8 chemical classes used in this study. Results are 
expressed as a percentage of the response to 1 mM glutamate, and refer to one experiment performed in triplicate. See Table 
7 for a complete summary of results obtained for 14 PAMs on 21 receptor mutants. 
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Figure 22: Effect of PAMs on glutamate-induced [35S]GTPγS binding in WT mGlu2 and mGlu2 with mutations located 
in transmembrane 6 (TM6). A to H, concentration-dependent enhancement of 4 μM glutamate-induced [35S]GTPγS 
binding by 8 PAMs, representative of the 8 chemical classes used in this study. Results are expressed as a percentage of 
the response to 1 mM glutamate, and refer to one experiment performed in triplicate. See Table 7 for a complete 
summary of results obtained for 14 PAMs on 21 receptor mutants. 
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Figure 20 displays the results obtained with mutations localized in transmembrane 4. 
As shown in Figure 20 and Table 8, the entire set of mutations in this receptor region seems 
to affect the activity of all compounds, except for mutation S688L (#1) which for most cases 
yielded results similar as for WT mGlu2. Mutation G689V/S688L/N735D (#5) disrupted the 
concentration-response curve for all the compounds, and a prominent potency/Emax decrease 
was seen for the compound representing the triazolopyridines, namely JNJ-42153605. 
Figure 21 displays the results from mutations localized in the regions of extracellular 
loop 2 (mutation H723V) and transmembrane 5. All the mutations seem to affect the 
activity of the compounds, but mutations N735D (#3) and L732A (#10) elicited the biggest 
shifts in the activity of the tested compounds. Interestingly, the effect of the EL2 mutation, 
H723V (#16), seems consistent between compounds from different chemical series. 
Finally, Figure 22 shows the results obtained for mutations localized in 
transmembrane 6. Mutation W773A (#11) affects the activity of all compounds, disrupting 
completely their ability to generate a concentration-response curve. This mutation caused a 4 
to 55-fold increase in EC50 of the compounds tested (Table 8). Although to a smaller extent, 
mutation F776A (#12) also consistently affects the activity of the compounds belonging to 
different chemical series. For the compound JNJ-35814090 (Figure 22D), this mutation also 
led to the complete loss of the receptor’s ability to respond to increasing concentrations of the 
compound. 
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  Stable  WT 
Transmembrane 3 
  (18) R635A (6) R636A (7) L639A (8) F643A (14) S644A 
  EC50 E max EC50 E max EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax 
1,4-Pyridones 
JNJ-40068782 139 206 87 201 378 246 Sc Sc 572 186 2396 89 216 174 
     1.0 1.0 4.3 1.2    6.5 0.9 27.4 0.4 2.5 0.9 
JNJ-41329782 68 215 57 202 Sc Sc Sc Sc 109 204 1142 84 180 196 
        1.0 1.0         2.9 1.0 20.0 0.4 3.2 1.0 
1,5-Pyridone 
JNJ-35814376 637 196 523 186 853 225 Sc Sc 1067 121 Sc Sc 625 139 
      1.0 1.0 1.6 1.2     2.0 0.7     1.2 0.7 
Triazolopyridines 
JNJ-46281222 8 214 6 211 Sc Sc Sc Sc Sc Sc 316 107 Sc Sc 
     1.0 1.0          55.6 0.5     
JNJ-42153605 6 224 5 214 Sc Sc Sc Sc Sc Sc 447 90 Sc Sc 
     1.0 1.0          84.3 0.4     
JNJ-46356479 91 227 59 204 Sc Sc Sc Sc Sc Sc 6783 86 Sc Sc 
     1.0 1.0          115.6 0.4     
JNJ-42329001 49 218 37 200 Sc Sc Sc Sc Sc Sc 5868 137 Sc Sc 
     1.0 1.0          156.8 0.7     
JNJ-43245046 6 224 7 227 Sc Sc Sc Sc 9 244 254 101 Sc Sc 
      1.0 1.0         1.4 1.1 38.7 0.4     
Isoquinolones 
JNJ-39226421 178 130 172 141 117 92 Sc 1 227 74 n.v. 36 119 110 
     1.0 1.0 0.7 0.7    1.3 0.5   0.3 0.7 0.8 
JNJ-40297036 143 139 148 147 1 1 Sc 1 1351 90 n.v. 49 Sc Sc 
      1.0 1.0         9.1 0.6   0.3     
Imidazopyridine JNJ-41482012   
172 97 175 101 Sc Sc Sc Sc Sc Sc n.v 36 Sc Sc 
    1.0 1.0               0.4     
THIIC JNJ-52149617 
113 166 114 159 Sc Sc Sc Sc 161 171 724 62 305 131 
   1.0 1.0       1.4 1.1 6.4 0.4 2.7 0.8 
BINA JNJ-35815013 
97 173 87 168 490 178 Sc Sc 1320 121 1414.1 84 108 153 
    1.0 1.0 5.6 1.1     15.2 0.7 16.3 0.5 1.2 0.8 
LY487379 JNJ-35814090 
173 116 156 128 Sc Sc Sc Sc 692 148 n.v. 53 276 105 
    1.0 1.0         4.4 1.2   0.4 1.8 0.8 
  
NT – not tested;  Sc – tested in screening assay;      – ratio EC50 mutant mGlu2 /EC50 WT > 3 or n.v – no value (absence of curve) 
Table 8: Potency (EC50) and relative Emax of the enhancement of glutamate-induced [
35S]GTPγS binding by 14 PAMs on WT and mutant receptors after transient transfection 
into CHO-K1 cells. Compound potency is presented as a ratio of EC50 between WT and mutant mGlu2. 
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Stable  WT 
Transmembrane 4 
  (1) S688L (2) G689V 
(4) G689V / 
S688L 
(5) N735D / 
G689V / S688L (15) V700L (17) S644A/V700L/H723V 
  EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax 
1,4-Pyridones 
JNJ-40068782 139 206 87 201 160 201 603 187 635 201 n.v. 42 Sc Sc 1262 163 
     1.0 1.0 1.8 1.0 6.9 0.9 7.3 1.0   0.2     14.4 0.8 
JNJ-41329782 68 215 57 202 NT NT NT NT 1349.0 124 NT NT Sc Sc 621 186 
       1.0 1.0     23.6 0.6       10.9 0.9 
1,5-Pyridone 
JNJ-35814376 637 196 523 186 520 206 2512 218 1445 125 n.v. 49 Sc Sc 2225 135 
     1.0 1.0 1.0 1.1 4.8 1.2 2.8 .7   0.3     4.3 0.7 
Triazolopyridines 
JNJ-46281222 8 214 6 211 20 159 83 229 61 215 767.2 203 Sc Sc  72 213 
     1.0 1.0 3.6 0.8 14.6 1.1 10.8 1.0 134.9 1.0     12.7 1.0 
JNJ-42153605 6 224 5 214 7 250 25 215 22 223 212 180 Sc Sc  47 209 
     1.0 1.0 1.3 1.2 4.7 1.0 4.2 1.0 40.0 0.8     8.8 1.0 
JNJ-46356479 91 227 59 204 NT NT 1349 269 309 197 3162.3 174 Sc Sc 692 215 
     1.0 1.0    23.0 1.3 5.3 1.0 53.9 0.9     11.8 1.1 
JNJ-42329001 49 218 37 200 NT NT 170 178 577 186 489.8 208 Sc Sc 115 230 
     1.0 1.0    4.5 0.9 15.4 0.9 13.1 1.0     3.1 1.1 
JNJ-43245046 6 224 7 227 NT NT 39 203 41 216 n.v. 142 Sc Sc 42 289 
     1.0 1.0    5.9 0.9 6.2 1.0   0.6     6.4 1.3 
Isoquinolones 
JNJ-39226421 178 130 172 141 NT NT NT NT n.v. 40 NT NT Sc Sc 539 95 
     1.0 1.0         0.3        3.1 0.7 
JNJ-40297036 143 139 148 147 209 147 537 117 264 114 n.v. 40 Sc Sc 389 101 
     1.  1.0 1.4 1.0 .6 0.8 1.8 0.8   0.3     2.6 0.7 
Imidazopyridine JNJ-41482012 
172 97 175 101 130.0 104 ~24 61 223 58 n.v 37 Sc Sc 274 73 
   1.0 1.0 0.7 1.0 ~0.1 0.6 1.3 0.6   0.4     1.6 0.7 
THIIC JNJ-52149617  
113 166 114 159 154 181 646 177 635 175 2896.3 56 Sc Sc 620 151 
   1.0 1.0 1.3 1.1 5.7 1.1 5.6 1.1 25.4 0.4     5.4 1.0 
BINA JNJ-35815013 
97 173 87 168 145 167 832 171 575 186 21379.6 44 Sc Sc 78 206 
   1.0 1.0 1.7 1.0 9.6 1.0 6.6 1.1 246.6 0.3     0.9 1.2 
LY487379 JNJ-35814090 
173 116 156 128 114 133 327 132 345 110 _n.v. 33 Sc Sc 670 111 
    1.0 1.0 0.7 1.0 2.1 1.0 2.2 0.9   0.3     4.3 0.9 
Table 8 (Cont.) 
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  Stable  WT 
Extracellular loop 2/Transmembrane 5 
  (16) H723V (9) D725A (19) M728A (20) 731A (10) L732A (3) N735D (21) V736A 
  EC50 E max EC50 
E 
max EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax 
1,4-Pyridones 
JNJ-40068782 139 206 87 201 549 189 Sc Sc Sc Sc 1 1 95 130 3019.95 70 Sc Sc 
     1.0 1.0 6.3 0.9            1.1 0.6 34.5 0.3     
JNJ-41329782 68 215 57 202 260 217 Sc Sc Sc Sc 245 247 63 140 NT NT Sc Sc 
       1.0 1.0 4.6 1.1         4.3 1.2 1.1 0.7       
1,5-Pyridone 
JNJ-35814376 637 196 523 186 1625 152 Sc Sc Sc Sc 1190 189 633 129 n.v. 81 Sc Sc 
     1.0 1.0 3.1 0.8         2.3 .0 1.2 0.7   0.4     
Triazolopyridines 
JNJ-46281222 8 214 6 211 Sc Sc Sc Sc  Sc Sc  Sc Sc  58 142 ~617 221 Sc Sc  
     1.0 1.0                10.3 0.7 102.0 1.0     
JNJ-42153605 6 224 5 214 28 226 Sc Sc  Sc Sc  Sc Sc  49 159 27 220 Sc Sc  
     1.0 1.0 5.2 1.1             9.2 0.7 5.2 1.0     
JNJ-46356479 91 227 59 204 195 220 Sc Sc Sc Sc Sc Sc 1015 131 NT NT Sc Sc 
     1.0 1.0 3.3 1.1             17.3 0.6        
JNJ-42329001 49 218 37 200 Sc Sc Sc Sc Sc Sc Sc Sc 576 141 NT NT Sc Sc 
     1.0 1.0                15.4 0.7        
JNJ-43245046 6 224 7 227 15 281 Sc Sc Sc Sc Sc Sc 82.5697 130 NT NT Sc Sc 
     1.0 1.0 2.3 1.2             12.6 0.6        
Isoquinolones 
JNJ-39226421 178 130 172 141 253 115 Sc Sc Sc Sc Sc Sc 57 73 NT NT Sc Sc 
     1.0 1.0 1.5 0.8             0.3 0.5        
JNJ-40297036 143 139 148 147 351 116 Sc Sc Sc Sc Sc Sc 329 78 n.v. 41 Sc Sc 
     1.0 1.0 2.4 0.8             2.2 0.5   0.3     
Imidazopyridine JNJ-41482012  
172 97 175 101 175 78 Sc Sc Sc Sc Sc Sc n.v 52 n.v 39 Sc Sc 
   1.0 1.0 1.0 0.8              0.5   0.4     
THIIC JNJ-52149617 
113 166 114 159 281 174 Sc Sc Sc Sc 285 169 357 91 2790.7 96 Sc Sc 
   1.0 1.0 2.5 1.1         2.5 1.1 3.1 0.6 24.5 0.6     
BINA JNJ-35815013 
97 173 87 168 Sc Sc Sc Sc Sc Sc Sc Sc 15 110 7413.1 74 Sc Sc 
   1.0 1.0               0.2 0.7 85.5 0.4     
LY487379 JNJ-35814090  
173 116 156 128 Sc Sc Sc Sc Sc Sc 834 109 n.v. 62 n.v. 40 Sc Sc 
    1.0 1.0             5.3 0.9   0.5   0.3     
Table 8 (Cont.) 
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  Stable  WT 
Transmembrane 6 
  (11) W773A (12) F776A (13) F780A 
  EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax 
1,4-Pyridones 
JNJ-40068782 139 206 87 201 n.v. 89 440 132 Sc Sc 
     1.0 1.0   0.4 5.0 0.7     
JNJ-41329782 68 215 57 202 1059 80 192 152 Sc Sc 
       1.0 1.0 18.5 0.4 3.4 0.8     
1,5-Pyridone 
JNJ-35814376 637 196 523 186 n.v. 46 Sc Sc 398.1 148 
     1.0 1.0   0.2    0.8 0.8 
Triazolopyridines 
JNJ-46281222 8 214 6 211 76 95 Sc Sc Sc Sc 
     1.0 1.0 13.3 0.4        
JNJ-42153605 6 224 5 214 n.v. 76 24 178 Sc Sc 
     1.0 1.0   0.4 4.6 0.8     
JNJ-46356479 91 227 59 204 2344.2 72 Sc Sc Sc Sc 
     1.0 1.0 40.0 0.4        
JNJ-42329001 49 218 37 200 1258.9 82 70 163 Sc Sc 
     1.0 1.0 33.6 0.4 1.9 0.8     
JNJ-43245046 6 224 7 227 361 92 7 158 Sc Sc 
     1.0 1.0 55.0 0.4 1.1 0.7     
Isoquinolones 
JNJ-39226421 178 130 172 141 n.v. 49 Sc Sc Sc Sc 
     1.0 1.0   0.3        
JNJ-40297036 143 139 148 147 n.v. 68 Sc Sc Sc Sc 
     1.0 1.0   0.5        
Imidazopyridine JNJ-41482012 
172 97 175 101 n.v 48 Sc Sc Sc Sc 
   1.0 1.0   0.5        
THIIC JNJ-52149617 
113 166 114 159 n.v. 51 125 118 218.8 156 
   1.0 1.0   0.3 1.1 0.7 1.9 1.0 
BINA JNJ-35815013 
97 173 87 168 n.v. 44 199 106 Sc Sc 
   1.0 1.0   0.3 2.3 0.6     
LY487379 JNJ-35814090 
173 116 156 128 631.0 63 n.v. 48 Sc Sc 
    1.0 1.0 4.0 0.5   0.4     
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  Stable  WT 
Extracellular loop 2/Transmembrane 5 
  (16) H723V (9) D725A (19) M728A (20) S731A (10) L732A (3) N735D (21) V736A 
  EC50 E max EC50 
E 
max EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax 
1,4-Pyridones 
JNJ-40068782 139 206 87 201 549 189 Sc Sc Sc Sc 1 1 95 130 3019.95 70 Sc Sc 
     1.0 1.0 6.3 0.9            1.1 0.6 34.5 0.3     
JNJ-41329782 68 215 57 202 260 217 Sc Sc Sc Sc 245 247 63 140 NT NT Sc Sc 
       1.0 1.0 4.6 1.1         4.3 1.2 1.1 0.7       
1,5-Pyridone 
JNJ-35814376 637 196 523 186 1625 152 Sc Sc Sc Sc 1190 189 633 129 n.v. 81 Sc Sc 
     1.0 1.0 3.1 0.8         2.3 1.0 1.2 0.7   0.4     
Triazolopyridines 
JNJ-46281222 8 214 6 211 Sc Sc Sc Sc  Sc Sc  Sc Sc  58 142 ~617 221 Sc Sc  
     1.0 1.0                10.3 0.7 102.0 1.0     
JNJ-42153605 6 224 5 214 28 226 Sc Sc  Sc Sc  Sc Sc  49 159 27 220 Sc Sc  
     1.0 1.0 5.2 1.1             9.2 0.7 5.2 1.0     
JNJ-46356479 91 227 59 204 195 220 Sc Sc Sc Sc Sc Sc 1015 131 NT NT Sc Sc 
     1.0 1.0 3.3 1.1             17.3 0.6        
JNJ-42329001 49 218 37 200 Sc Sc Sc Sc Sc Sc Sc Sc 576 141 NT NT Sc Sc 
     1.0 1.0                15.4 0.7        
JNJ-43245046 6 224 7 227 15 281 Sc Sc Sc Sc Sc Sc 82.5697 130 NT NT Sc Sc 
     1.0 1.0 2.3 1.2             12.6 0.6        
Isoquinolones 
JNJ-39226421 178 130 172 141 253 115 Sc Sc Sc Sc Sc Sc 57 73 NT NT Sc Sc 
     1.0 1.0 1.5 0.8             0.3 0.5        
JNJ-40297036 143 139 148 147 351 116 Sc Sc Sc Sc Sc Sc 329 78 n.v. 41 Sc Sc 
     1.0 1.0 2.4 0.8             2.2 0.5   0.3     
Imidazopyridine JNJ-41482012  
172 97 175 101 175 78 Sc Sc Sc Sc Sc Sc n.v 52 n.v 39 Sc Sc 
   1.0 1.0 1.0 0.8              0.5   0.4     
THIIC JNJ-52149617 
113 166 114 159 281 174 Sc Sc Sc Sc 285 169 357 91 2790.7 96 Sc Sc 
   1.0 1.0 2.5 1.1         2.5 1.1 3.1 0.6 24.5 0.6     
BINA JNJ-35815013 
97 173 87 168 Sc Sc Sc Sc Sc Sc Sc Sc 15 110 7413.1 74 Sc Sc 
   1.0 1.0               0.2 0.7 85.5 0.4     
LY487379 JNJ-35814090  
173 116 156 128 Sc Sc Sc Sc Sc Sc 834 109 n.v. 62 n.v. 40 Sc Sc 
    1.0 1.0             5.3 0.9   0.5   0.3     
Table 8 (Cont.) 
 
 
 
75 
 
 
    
  Stable  WT 
Transmembrane 6 
  (11) W773A (12) F776A (13) F780A 
  EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax 
1,4-Pyridones 
JNJ-40068782 139 206 87 201 n.v. 89 440 132 Sc Sc 
     1.0 1.0   0.4 5.0 0.7     
JNJ-41329782 68 215 57 202 1059 80 192 152 Sc Sc 
       1.0 1.0 8.5 0.4 3.4 0.8     
1,5-Pyridone 
JNJ-35814376 637 196 523 186 n.v. 46 Sc Sc 398.1 148 
     1.0 1.0   0.2    0.8 0.8 
Triazolopyridines 
JNJ-46281222 8 214 6 211 76 95 Sc Sc Sc Sc 
     1.0 1.0 13.3 0.4        
JNJ-42153605 6 224 5 214 n.v. 76 24 178 Sc Sc 
     1.0 1.0   0.4 4.6 0.8     
JNJ-46356479 91 227 59 204 2344.2 72 Sc Sc Sc Sc 
     1.0 1.0 40.0 .4        
JNJ-42329001 49 218 37 200 1258.9 82 70 163 Sc Sc 
     1.0 1.0 33.6 0.4 1.9 0.8     
JNJ-43245046 6 224 7 227 361 92 7 158 Sc Sc 
     1.0 1.0 55.0 0.4 1.1 0.7     
Isoquin lones 
JNJ-39226421 178 130 172 141 n.v. 49 Sc Sc Sc Sc 
     1.0 1.0   0.3        
JNJ-40297036 143 139 148 147 n.v. 68 Sc Sc Sc Sc 
     1.0 1.0   0.5        
Imidazopyridine JNJ-41482012 
172 97 175 101 n.v 48 Sc Sc Sc Sc 
   1.0 1.0   0.5        
THIIC JNJ-52149617 
113 166 114 159 n.v. 51 125 118 218.8 156 
   1.0 1.0   0.3 1.1 0.7 1.9 1.0 
BINA JNJ-35815013 
97 173 87 168 n.v. 44 199 106 Sc Sc 
   1.0 1.0   0.3 2.3 0.6     
LY487379 JNJ-35814090 
173 116 156 128 631.0 63 n.v. 48 Sc Sc 
    1.0 1.0 4.0 0.5   0.4     
 
 
Table 8 (Cont.) 
 
A4 - 06094 - Ana Farinha - thesis binnenwerk.indd   75 28/06/2012   9:59:01
 
 
 
 
  
A4 - 06094 - Ana Farinha - thesis binnenwerk.indd   76 28/06/2012   9:59:01
 
 
 
 
 
Chapter 4 
Discussion
A4 - 06094 - Ana Farinha - thesis binnenwerk.indd   77 28/06/2012   9:59:01
 
 
78 
 
The pursuit for alternative therapeutic approaches devoid of the disadvantages 
associated with the use of orthosteric agonists has conferred prominence to allosteric 
modulators, namely PAMs. The recent emergence of PAMs as highly attractive subtype-
selective mGlu2 receptor modulators makes it important to investigate the molecular factors 
mediating the interaction between these compounds and the receptor, as a way not only to 
understand how these compounds bind and activate the receptor, but also to enable the 
development of future more optimal compounds.  
In the past decade, a number of studies have focused on the investigation of the 
binding mode of allosteric modulators on mGlu receptors. The different studies have 
suggested that residues in TM 3, 4, 5, 6 and 7, and also in the EL2, constitute the allosteric 
binding pocket for allosteric modulators. The reported mutations do not necessarily affect the 
binding of all allosteric ligands, although it has been shown that different compounds may 
share an overlapping binding site – even if they exhibit opposite effects towards the receptor 
(PAMs versus NAMs). 
In the present study, the molecular interaction of 14 PAMs with the mGlu2 receptor 
was elucidated. For that, the activity of these compounds on WT and point-mutated mGlu2 
receptors was compared in order to identify amino acids potentially important for the 
interaction between PAMs and the mGlu2 receptor. In previous work, the compounds tested 
in this study were shown not to displace [3H]-LY341495 binding, confirming their binding to 
an allosteric binding site (data not shown); additionally, previous studies revealed that these 
compounds exhibit selective positive allosteric modulation at recombinant mGlu2 receptors 
(data not shown). 
 
 
4.1. Expression of WT and mutant mGlu2 receptors 
 
Western blot analysis revealed a similar pattern in the expression of WT and mutant 
receptors, although membranes of CHO-K1 cells stably transfected with WT mGlu2 receptor 
revealed apparent higher expression levels. In addition to Western blot analysis, saturation 
binding assays were performed for mutations S688L, G689V, N735D, S688L/G689V and 
S688L/G689V/N735D which enabled the quantification of the total amount of receptors. 
Although this quantification was not carried out for all the mutations, it clearly shows that 
mutant receptors have variable expression levels, displaying lower expression levels when 
compared to the stable transfection.  
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4.2. Comparison between the affinity and potency for glutamate between WT and 
mutant mGlu2 
 
Despite the confirmation that mutant receptors are being expressed by CHO-K1 cells, 
their ability to bind the agonist, glutamate, also needed to be confirmed to assure that the 
receptor could achieve the conformation required for agonist binding. In fact, glutamate was 
able to displace [3H]-LY341495 in a concentration-dependent manner, both from the WT 
receptor stably expressed in CHO-K1 cells and from transiently transfected WT as well as 
mutant receptors. Accordingly, the IC50 values were overall similar. These results confirm 
that mutant receptors are not only being expressed by CHO-K1 cells, but they also are able to 
bind glutamate in a similar way as WT, indicating that they are still able to acquire the 
conformation needed for agonist binding. 
Further studies were carried out to assess the functional properties of mutant 
receptors. Concentration-response curves for glutamate-induced [35S]GTPγS binding were 
performed in order to compare the functional activity of WT and mutant receptors. Even 
though glutamate response amplitudes varied (likely as a result of differences in expression 
levels and/or transfection efficiency), mutated receptors elicited glutamate concentration-
response curves with resulting potency values that were similar to those of WT receptor. This 
result suggests that the mutations did not have a significant effect on the potency of glutamate 
towards the receptor and confirmed that the mutant receptors were functionally active.  
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4.3. Effect of mGlu2 mutations on the activity of positive allosteric modulators 
 
A brief overview of the results presented in Figures 19-22 and Table 4 makes it 
possible to infer that different mutations have different effects on the activity of the PAMs 
tested in this study, which suggests that the different compounds may not share the exact 
same binding mode as expected. Given the diversity of the chemical structures of the 
compounds, they will form subtly different interactions. Several studies, as the ones 
performed by Hemstapat et al. (2006, 2007), showed indeed evidence of different allosteric 
binding pockets for different allosteric modulators. 
 
 
Effect of mGlu2 mutations on the different chemical classes 
 
When analyzing the effect of mutant mGlu2 receptors on the activity of 1,4-
Pyridones, mutations F643A, S688L/G689V/N735D, N735D and W773A were shown to 
decrease the enhancing activity of this compound, with high increases in EC50 values (18.5 to 
34.7-fold increase) and a reduction in the efficacy of the compounds. Interestingly, mutations 
H723V, S644A/V700L/H723V and F776A (and also the mutation G689V/S688L in JNJ 
41329782) caused a considerable increase in EC50 values (3.4 to 14.4-fold increase), but the 
efficacy was not severely affected, which can indicate that this mutation affected the affinity 
of the compound towards the receptor. Figure 23 illustrates the 3D position of the mutated 
amino acids in the mGlu2 receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: 3D representation of the receptor and the mutations that seem 
to affect the binding of 1,4-Pyridones (the two images represent different 
angles). 
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Figure 24: 3D representation of the receptor and the mutations that seem 
to affect the binding of triazalopyridines (the two images represent 
different angles). 
For the 1,5-pyridones tested on this study, mutations G689V, G689V/S688L, H723V 
and S644A/V700L/H723V led to an increase in the EC50 (2.76 to 4.8-fold increase) but to 
small effects on the relative efficacy, whereas mutations N735D, N735D/G689V/S688L and 
W773A completely disrupted the activity of this compound. 
For triazolopyridines, the most potent of the compounds tested (EC50 vary between 6 
and 91 nM), the effects of the mutations in the different compounds were overall consistent. 
Mutations S688L/G689V/N735D (and, even though with smaller effects, each one of the 
correspondent single mutations), F643A, L732A, W773A and S644A/V700L/H723V show a 
prominent increase in EC50 values for the different compounds. The mutations F643A and 
W773A caused major decreases in the relative efficacy of this class of compounds. 
Interestingly, mutation L732A consistently and somewhat preferably affects this class of 
compounds. Figure 24 illustrates the 3D position of the mutations that seem to be important 
for the activity of this class of compounds. Compounds belonging to triazalopyridine class 
were, by far, the most affected by the mutations tested: an overview of the ratios between the 
EC50 of the compounds on mutant and WT mGlu2 clearly demonstrates that the mutations 
have a greater impact on the activity of these compounds. Interestingly, this is accompanied 
by the high potency of this class of molecules at WT receptor. This increased potency arises 
due to a more optimal interaction with the protein target. Therefore given this highly 
optimized fit with the mGlu2 receptor it is natural to expect they would be most sensitive to 
changes in the binding site. Consequently, L732 seems to be important to render that 
additional interaction, or indeed increase compound’s potencies. 
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For isoquinolones, mutations F643A and W773A completely abolished the PAMs 
activity. The EC50 was impossible to calculate due to a completely disruption of a 
concentration-response curve. Mutation S644A/V700L/H723V caused a 2.6 to 3.1-fold 
increase in EC50 and a reduction in the relative efficacy. Particularly for the compound JNJ 
40297036, mutation L639A caused a 9.1-fold increase in EC50 and a relative efficacy of 
90%, against the 141% observed for the WT. The lack of data for some mutations of the 
transmembrane 4 does not enable the assessment of their effect on compounds activity. 
Nevertheless, mutation G689V and the triple mutation S688L/G689V/N735D seem to affect 
the binding of JNJ-40297036. Interestingly, mutant L732A increased five times the activity 
of the isoquinolone compound, JNJ-39226421.  
The enhancing property of the imidazopyridine was abolished in mutants N735D, 
N735D/G689V/S688L, F643A, L732A and W773A. These mutations completely abolished 
the receptor capacity of responding to increasing PAM concentrations. 
For the reference compounds acetophenone, BINA and LY487379, mutations N735D, 
N735D/G689V/S688L (Figure 25), F643A and W773A show relatively consistent results. 
These mutations caused an increase in EC50 values (4 to 246.6-fold increase), or a complete 
obliteration of the PAM effect. BINA showed a ~ 250-fold increase in EC50 for the mutation 
N735D/G689V/S688L, suggesting the importance of this binding pocket for this compound. 
As for the isoquinone compound JNJ-39226421, also for BINA the mutation L732A 
increased its activity three times. Interestingly, mutations G689V, G689V/S688L, L639A, 
L732A, F776A, S644A/V700L/H723V, R635A and S731A differently affected these three 
compounds, causing an increase in the EC50 for one of them, but having no effect on the 
others. 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: 3D representation of the receptor and the mutations that seem 
to affect the binding of reference compounds (the two images represent 
different angles). 
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Mutation W773A consistently affected the binding off all the compounds, without 
exception. W773 is located on transmembrane 6 and is conserved in class C GPCRs. Previous 
mutagenesis studies have shown that the amino acid located at the same position at other 
mGlu receptors (namely, mGlu1 and mGlu5) is important for the binding of allosteric 
modulators (Malherbe et al., 2003a,b; Malherbe et al., 2006; Muhlemann et al., 2006). 
Accordingly, the modeling studies performed for this work suggest that this amino acid is 
part of a hydrophobic cluster within the expected transmembrane allosteric binding site, 
formed also by the amino acids F643, L732, W773, and F776. This hydrophobic cluster 
interacts with the ligand in its predicted binding mode, as Figure 26 displays. Therefore, the 
high impact of this mutation on the binding of all the compounds tested is consistent with the 
predictions of the homology model. 
As mentioned above, mutation L732A increased the potency of two compounds: JNJ-
35815013 (BINA) and JNJ-39226421 (isoquinolone). Although the reasons of this potency 
increase are unknown, it is interesting to notice that this effect was seen for only one of the 
compounds belonging to isoquinolone chemical class.  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 26: Modelled mGlu2 receptor structure showing bound 
pose for Janssen mGlu2 PAM in surface representation and the 
cluster of hydrophobic amino acids, Phe643, Leu732, Trp773, 
and Phe776. 
 
A4 - 06094 - Ana Farinha - thesis binnenwerk.indd   83 28/06/2012   9:59:02
 
 
84 
 
mGlu2/3 sequences comparison 
 
When assessing the impact of the mutations selected for this study based on the 
differences between mGlu2 and mGlu3 receptor sequences (S644A, V700L and H723V), 
only the triple mutation caused major shifts in the activity of PAMs. This large effect did not 
occur when using the single amino acid mutations (only the mutation H723V led to a loss of 
effect in several compounds when applied alone) (Table 8). This suggests that these three 
amino acids may form an important binding pocket for the activity of PAMs and may be 
responsible for their subtype-specificity. However, these mutations represent only a small 
part of the mutations that were selected based on this criteria (Table 4, Methods section). 
Therefore, the testing of the other mutations is needed in order to have more conclusive 
results. The amino acids S688, Gly689 and Asn735, previously identified in literature, were 
also selected for mutagenesis based on the sequence divergence between mGlu2 and mGlu3 
receptor (Rowe et al., 2008) and the high impact of G689V, N735D and the double and triple 
mutations of these three amino acids confirms their importance in the mGlu2 subtype-
selective properties of PAMs.  
 
 
Overall important amino acids 
 
The overall observation of the ratios between the EC50 of mutant and WT mGlu2 
receptors clearly highlights some trends in the effects of the different mutation on PAM 
performance: mutations F643A, G689V, W773A, S688L/G689V, S688L/G689V/N735D (but 
not the individual mutations) and S644A/V700L/H723V (but not the individual mutations) 
have a general impact on the activity of all the structurally distinct compounds (Figure 27). 
Therefore, these amino acids seem to participate in the structure of a common binding pocket 
for PAM. The differences in the effects observed for other mutations are possibly a 
consequence of the features specific for each structure. 
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 When assessing the effects of mutations on PAMs activity (in our case using 
[35S]GTPγS binding assay), it is important to clarify the possible effects that a mutation can 
have in the receptor function: 1) the mutation can prevent the receptor to acquire a 
functionally active conformation in the membrane, regardless of the activity of the compound 
(it can cause, for example, an increase in the internalization of the receptor, disabling the 
receptor to localize in the membrane); 2) the mutations may enable the binding of the 
compound, but lead to a conformation that does not allow the interaction with G protein and, 
therefore, no functional response is detected; 3) the mutated receptor does not allow the 
binding of the compound or decreases the affinity of the compound for binding to the 
receptor. In the first and second situations, we hypothesize that the receptor would not be able 
to be activated even by glutamate, in which case this would be picked up in the glutamate 
concentration-response curve. Still, the fact that not only potency but also efficacy (Emax) for 
some compounds is decreased, may suggest that certain mutations affect the receptor 
signaling machinery in some way. In the last situation, although the effects of each mutation 
are assessed through the impact on a functional response (efficacy), this is in fact the result of 
an upstream event – the binding of the compound (affinity). As a next step, it would hence be 
important to assure that the compound is actually able to bind the mutant receptor which 
could be investigated through radioligand binding studies using a tritiated form of an 
allosteric modulator or using a tritiated agonist and assessing the effects of the PAM on its 
binding properties. 
Figure 27: 3D representation of the receptor and the mutations that seem 
to affect the binding of the PAMs tested in these study (the two images 
represent different angles). 
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The proven success of GPCRs as drug targets for the treatment of CNS disorders 
renders them attractive targets of research. Specifically, the mGlu2 receptor is currently being 
pursued as the target for the treatment of several neurological and psychiatric diseases. The 
quest for increasingly potent and selective ligands for this receptor is leading to the 
identification of novel ligands, with improved physicochemical and pharmacokinetic 
properties. Accordingly, mGlu2 positive allosteric modulators constitute an attractive 
approach for the selective activation of this receptor. Therefore, the identification of the 
molecular determinants of mGlu2 receptor-PAMs binding is highly attractive.  
The present study provides further additional insight on the interactions that drive the 
activity of PAMs towards mGlu2 receptor. Surprisingly, not only did double or triple 
mutations affect the activity of the PAMs tested, but a strong and consistent effect was also 
observed for single amino acid mutations, which enabled the identification of specific 
molecular determinants that might be important for the activity of these compounds. 
Mutations F643A, G689V, W773A, S688L/G689V, S688L/G689V/N735D and 
S644A/V700L/H723V were shown to have a general impact on the activity of all the 
structurally distinct compounds. Interestingly, the mutations found by Lundström et al (2011) 
to be important for NAMs binding show different results for the PAMs tested in this study: 
R636A and F780A, two mutations with a high effect on the binding of NAMs, have no effect 
on the activity of the PAMs tested. Still, mutations F643A, H723V, L732A, N735D and 
R635A were shown by Lundström et al. to have an effect on NAMs, also seem to affect the 
activity of PAMs which may suggest common binding sites for NAMs and PAMs.  
The knowledge obtained from the mapping of new allosteric modulators is helping to 
understand the regions of the mGlu receptors that are critical for modulation of positive 
allosteric modulators activity. Ultimately, this study will contribute to guide research towards 
the achievement of more selective and potent drugs. 
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Appendix 1: Complete names of the compounds mentioned in the text 
Abbreviation Name 
(+)-ACPT-III (3RS,4RS)-1-aminocyclopentane-1,3,4-tricarboxylic acid 
(1S, 3R)-
ACPD 
1S,3R-1-aminocyclopentane-trans-1,3-dicarboxylic acid 
(2R, 4R)-
APDC 
(2R, 4R)-4-Aminopyrrolidine-2,4-dicarboxylic acid 
(RS)-PPG (RS)-4-Phosphonophenylglycine 
(S)-3,4-DCPG (S)-3,4-Dicarboxyphenylglycine 
(S)-3,5-DHPG 3,5-Dihydroxyphenylglycine 
1S,3S-ACPD 1S,3S-1-aminocyclopentane-1,3-dicarboxylic acid 
2S,4S-4MG 2S,4S-4-methylglutamic acid 
ABH x D-I (1S,2S,4S,5S)-2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid 
ACPT-I 1-aminocyclopentane-1,3,4-tricarboxylic acid 
ADX47273 
(S)-(4-fluorophenyl)-(3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-
yl]piperidin-1-yl)methanone 
AMN082 N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride 
Bay 36-7620 
(3aS6aS)-6a-naphtalen-2-ylmethyl-5-methyliden-hexahydro-
cyclopental[c]furan-1-on 
BINA 
3'-[[(2-Cyclopentyl-2,3-dihydro-6,7- dimethyl-1-oxo-1H-inden-5-
yl)oxy]methyl]-[1,1'-biphenyl]-4-carboxylic acid 
CDPPB 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide 
CHPG 2-chloro-5-hydroxyphenylglycine 
CPCCOEt 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester 
CPPG (RS)-a-cyclopropyl-4-phosphonophenylglycine 
CPPHA 
N-[4-Chloro-2-(phthalimidomethyl)phenyl]salicylamide N-[4-Chloro-2-
[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-
hydroxybenzamide 
CTZ Cyclothiazide 
DCG-IV (2S,2’ R,3’R)-2-(2’,3’)-Dicarboxycyclopropyl glycine 
DFB 3,3'-Difluorobenzaldazine 
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E-CBQA 1-amino-3-[2’-3’,5’-dioxo-1’,2’,4’-oxadiazo-lidinyl)] cyclobutane-1-
carboxylic acidcyclobutane-1-carboxylic acid 
EM-TBPC 
1-ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-
dihydro-pyrimidine-5-carbonitrile 
FTIDC 
4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2, 3-triazol-4-yl]-N-isopropyl-
N-methyl-3,6-dihydropyridine-1(2H)-carboxamide 
HYDIA 
(1S,2R,3R,5R,6S)-2-amino-3-hydroxybicyclo[3.1.0]hexane-2,6-
dicarboxylic acid 
JNJ16259685 
(3,4-Dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-(cis-4-methoxycyclohexyl)-
methanone 
L-AP4 (2S)-2-amino-4-phosphonobutanoic acid 
L-CBG-I (2S,1’S,2’S)-2-(2-carboxycyclobutyl)glycine 
LCCG-I (2S,1’S,2’S)-2-(carboxycyclopropyl)glycine 
L-F2CCG-I (2S,1’S,2’S)-3’3’-difluoro-2-(carboxycyclopropyl)glycine 
LY341495 
2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl)propionic 
acid 
LY354740 (1S,2S,5R,6S)-(+)-2-aminobicylco[3.1.0]hexane-2,6-dicarboxylic acid 
LY367385 (S)-(+)-α-Amino-4-carboxy-2-methylbenzeneacetic acid 
LY379268 (–)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylic acid 
LY38979 (–)-2-thia-4-aminobicylco[3.1.0]hexane-4,6-dicarboxylic acid 
LY487379 
2,2,2-Trifluoro-N-[4-(2-methoxyphenoxy)phenyl]-N-(3-
pyridinylmethyl)ethanesulfonamidehydrochloride 
MAP4 (S)-a-methyl-2-amino-4-phosphonobutanoic acid 
MCPG α-Methyl-4-carboxyphenylglycine 
MGS0028 
(1R,2S,5S,6S)-2-amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-
dicarboxylic acid 
MGS0039 
(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-
fluorobicyclo[3.1.0] hexane-2,6-dicarboxylic acid 
MMPIP 
6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazolo[4,5-c]pyridin-
4(5H)-one 
MNI-135 [3-(7-iodo-4-oxo-4,5-dihydro-3H-benzo[1,4]diazepin-2-yl)-benzonitrile] 
MNI-136 
[7-bromo-4-(3-pyridin-3-yl-phenyl)-1,3-dihydro-benzo [1,4] diazepin-2-
one] 
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MNI-137 
[4-(7-bromo-4-oxo-4,5-dihydro-3H-benzo[1,4]diazepin-2-yl)-pyridine-2-
carbonitrile] 
MPEP 2-methyl-6-(phenylethynyl)pyridine 
MTEP 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine 
NAAG N-acetylaspartylglutamate 
NPS 2390 2-quinoxaline-carboxamide-N-adamantan-1-yl 
PHCCC N-phenyl-7-(hydroxyhydroxy-imino) cyclopropa[b]chromen-1a-
carboxamide 
R214127 [3H]1-(3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-2-phenyl-1-ethanone 
Ro 01-6128 (Diphenylacetyl)-carbamic acid ethy ester 
Ro 67-4853 (9H-Xanthen-9-ylcarbonyl)-carbamic acid butyl ester 
Ro 67-7476 (2S)-2-(4-Fluorophenyl)-1-[(4-methylphenyl)sulfonyl]-pyrrolidine 
RO4988546 
5-[7-trifluoromethyl-5- (4 - trifluoromethyl-phenyl)-pyrazolo[1,5-
a]pyrimidin-3-ylethynyl]-pyridine-3-sulphonic acid 
RO5488608 
3′-(8-methyl-4-oxo-7- trifluoromethyl -4,5-dihydro-3H-
benzo[b][1,4]diazepin-2-yl)-biphenyl-3-sulphonic acid 
S-4MeGlu S-4-methyleneglutamic acid 
S-AP4 S-4-Phosphono-2-aminobutyric acid 
S-Homo-
AMPA 
2-Amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid 
SIB-1757 6-methyl-2-(phenylazo)pyridin-3-ol 
SIB-1893 (E)-2-methyl-6-styrylpyridine 
S-SOP S-serine-O-phosphate 
VU0080421 pyrazolo[3,4-d]pyrimidine 
VU0155041 cis-2-[[(3,5-Dichlorophenyl)amino]carbonyl]cyclohexanecarboxylic acid 
VU29 N-(1,3-Diphenyl-1H-pyrazolo-5-yl)-4-nitrobenzamide 
VU71 4-nitro-N-(1,4-diphenyl-1Hpyrazol-5-yl)benzamide 
YM-298198 
6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-
carboxamide 
Z-CBQA 
(Z)-1-Amino-3-[2’-(3’,5’-dioxo-1’,2’,4’-oxadiazolidinyl-cyclobutane-1-
carboxylic acid 
Z-cyclopentyl 
AP4  
cis-(±)-1-Amino-3-phosphonocyclopentane carboxylic acid 
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Appendix 2: mGlu2 receptor positive allosteric modulators tested in this study 
 
 
1,4-Pyridones JNJ-40068782 
JNJ-41329782 
 
1,5-Pyridones JNJ-35814376 
 
Triazolopyridines JNJ-46281222 
JNJ-42153605 
JNJ-46356479 
JNJ-42329001 
JNJ-43245046 
 
Isoquinolones JNJ-39226421 
JNJ-40297036 
 
Imidazopyridine JNJ-41482012 
 
THIIC  JNJ-52149617 
 
BINA    JNJ-35815013 
 
LY487379  JNJ-35814090 
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Appendix 4: Potency (EC50) and relative Emax of the enhancement of glutamate-induced [
35
S]GTPγS binding by 14 PAMs on WT and mutant receptors after transient transfection into CHO-K1 cells. 
Compound potency is presented as a ratio of EC50 between WT and mutant mGlu2. (SD: standard deviation)
EC50 SD n mean SD n mean SD n mean SD n mean SD n mean SD n mean mean mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n
JNJ-40068782 139 47 15 206 13 15 87 27 7 201 23 7 378 27 3 246 21 3 Sc Sc 572 225 3 186 20 3 2395.6 862 3 89 25 3 216 111 3 174 32 3
1.0 1.0 4.3 1.2 6.5 0.9 27.4 0.4 2.5 0.9
JNJ-41329782 68 15 10 215 14 10 57 15 4 202 9 4 Sc Sc Sc Sc 109 16 2 204 15 2 1142 256 3 84 10 3 180 144 3 196 51 3
1.0 1.0 2.9 1.0 20.0 0.4 3.2 1.0
JNJ-35814376 637 147 12 196 16 12 523 163 5 186 14 5 853 83 2 225 86 3 Sc Sc 1067 822 3 121 8 3 Sc Sc 625 165 3 139 14 3
1.0 1.0 1.6 1.2 2.0 0.7 1.2 0.7
JNJ-46281222 8 4 6 214 6 6 6 5 3 211 25 3 Sc Sc Sc Sc Sc Sc 316 --- 1 107 12 2 Sc Sc
1.0 1.0 55.6 0.5
JNJ-42153605 6 4 9 224 12 9 5 3 3 214 30 3 Sc Sc Sc Sc Sc Sc 447 323 2 90 1 2 Sc Sc
1.0 1.0 84.3 0.4
JNJ-46356479 91 28 9 227 10 9 59 27 4 204 13 4 Sc Sc Sc Sc Sc Sc 6782.9 2171 2 86 9 3 Sc Sc
1.0 1.0 115.6 0.4
JNJ-42329001 49 18 9 218 16 9 37 9 4 200 30 4 Sc Sc Sc Sc Sc Sc 5867.8 1045 2 137 33 3 Sc Sc
1.0 1.0 156.8 0.7
JNJ-43245046 6 1 9 224 11 9 7 1 3 227 11 3 Sc Sc Sc Sc 9 1 2 244 26 2 254 49 2 101 4 3 Sc Sc
1.0 1.0 1.4 1.1 38.7 0.4
JNJ-39226421 178 36 9 130 16 9 172 37 4 141 20 4 117 --- 1 92 30 2 Sc Sc 227 97 2 74 8 2 n.v. 2 36 11 2 119 10 2 110 20 2
1.0 1.0 0.7 0.7 1.3 0.5 0.3 0.7 0.8
JNJ-40297036 143 31 10 139 8 10 148 25 4 147 9 4 Sc Sc Sc Sc 1351 1073 3 90 15 3 n.v. 3 49 3 Sc Sc
1.0 1.0 9.1 0.6 0.3
JNJ-41482012 172 27 8 97 7 8 175 28 3 101 2 3 Sc Sc Sc Sc Sc Sc n.v 2 36 2 Sc Sc
1.0 1.0 0.4
JNJ-52149617 113 23 17 166 16 17 114 42 8 159 26 8 Sc Sc Sc Sc 161 20 4 171 20 4 724 --- 1 62 10 3 305 69 3 131 16 3
1.0 1.0 1.4 1.1 6.4 0.4 2.7 0.8
JNJ-35815013 97 34 12 173 9 12 87 35 7 168 22 7 490 --- 1 178 79 3 Sc Sc 1320 86 2 121 6 3 1414.1 231 3 84 42 4 108 39 3 153 17 3
1.0 1.0 5.6 1.1 15.2 0.7 16.3 0.5 1.2 0.8
JNJ-35814090 173 65 16 116 9 16 156 102 8 128 12 8 Sc Sc Sc Sc 692 --- 1 148 35 3 n.v. 2 53 19 3 276 88 3 105 10 3
1.0 1.0 4.4 1.2 0.4 1.8 0.8
mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n mean mean mean SD n mean SD n
JNJ-40068782 160 145 3 201 22 3 603 212 4 187 23 4 635 416 3 201 6 3 n.v. 0 2 42 18 3 Sc Sc 1262 123 2 163 12 3
1.8 1.0 6.9 0.9 7.3 1.0 0.2 14.4 0.8
JNJ-41329782 NT NT NT NT 1349 --- 1 124 --- 1 NT NT Sc Sc 621 170 2 186 2 2
23.6 0.6 10.9 0.9
JNJ-35814376 520 59 2 206 2 2 2512 --- 1 218 --- 1 445 --- 125 7 2 n.v. --- 1 49 --- 1 Sc Sc 2225 573 2 135 23 3
1.0 1.1 4.8 1.2 0.7 0.3 4.3 0.7
JNJ-46281222 20 --- 1 159 --- 1 83 69 2 229 7 2 61 52 2 215 0 2 767.17 695 2 203 8 3 Sc Sc 72 43 2 213 6 2
3.6 0.8 14.6 1.1 10.8 1.0 134.9 1.0 12.7 1.0
JNJ-42153605 7 2 2 250 25 2 25 4 2 215 14 2 22 11 2 223 4 2 212 240 3 180 22 3 Sc Sc 47 4 3 209 15 3
1.3 1.2 4.7 1.0 4.2 1.0 40.0 0.8 8.8 1.0
JNJ-46356479 NT NT 1349 --- 1 269 --- 1 309 --- 1 197 33 2 3162.3 --- 1 174 3 2 Sc Sc 692 0 1 215 4 2
23.0 1.3 5.3 1.0 53.9 0.9 11.8 1.1
JNJ-42329001 NT NT 170 --- 1 178 --- 1 577 598 2 186 35 2 489.78 0 1 208 7 2 Sc Sc 115 42 2 230 8 2
4.5 0.9 15.4 0.9 13.1 1.0 3.1 1.1
JNJ-43245046 NT NT 39 --- 1 203 --- 1 41 --- 1 216 --- 1 n.v. --- 1 142 --- 1 Sc Sc 42 34 2 289 74 2
5.9 0.9 6.2 1.0 0.6 6.4 1.3
JNJ-39226421 NT NT NT NT n.v. --- 1 40 --- 1 NT NT Sc Sc 539 130 2 95 1 2
0.3 3.1 0.7
JNJ-40297036 209 --- 1 147 --- 1 537 --- 1 117 --- 1 264 34 2 114 0 2 n.v. 2 40 1 2 Sc Sc 389 16 3 101 12 3
1.4 1.0 3.6 0.8 1.8 0.8 0.3 2.6 0.7
JNJ-41482012 130 46 2 104 9 2 ~24 --- 2 61 --- 2 223 142 2 58 11 2 n.v 2 37 1 2 Sc Sc 274 50 3 73 3 3
0.7 1.0 ~0.1 0.6 1.3 0.6 0.4 1.6 0.7
JNJ-52149617 154 120 3 181 38 3 646 324 3 177 43 3 635 280 3 175 49 3 2896.3 376 2 56 22 3 Sc Sc 620 78 3 151 12 3
1.3 1.1 5.7 1.1 5. .1 25.4 0.4 5.4 1.0
JNJ-35815013 145 118 3 167 13 3 832 720 3 171 32 3 575 270 3 186 0 3 21380 --- 1 44 9 3 Sc Sc 78 26 3 206 32 3
1.7 1.0 9.6 1.0 6.6 1.1 246.6 0.3 0.9 1.2
JNJ-35814090 114 19 3 133 20 3 327 257 3 132 28 3 345 106 3 110 7 3 _n.v. 0 3 33 23 3 Sc Sc 670 85 3 111 14 3
0.7 1.0 2.1 1.0 2.2 0.9 0.3 4.3 0.9
NT Not tested
Sc Tested in screening assay 
If ratio > 3 or n.v
n.v. No value (absence of curve)
(1) S688L (2) G689V (4) G689V / S688L
Stable WT
Transmembrane 4
(15) V700L (17) S644A/V700L/H723V(5) N735D / G689V / S688L
(18) R635A (6) R636A (7) L639A (8) F643A (14) S644A
Transmembrane 3
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Appendix 4: (cont.)
mean SD n mean SD n mean mean mean mean mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n mean mean
JNJ-40068782 549 77 3 189 25 3 Sc Sc Sc Sc Sc Sc 95 12 3 130 12 3 3019.95 1 70 15 3 Sc Sc
6.3 0.9 1.1 0.6 0.3
JNJ-41329782 260 135.6 3 217 72 3 Sc Sc Sc Sc 245 --- 1 247 19 2 63 7 3 140 5 3 NT NT Sc Sc
4.6 1.1 4.3 1.2 1.1 0.7
JNJ-35814376 1625 368 3 152 31 3 Sc Sc Sc Sc 1190 97 2 189 12 2 633 229 3 129 9 3 n.v. --- 0 81 --- 1 Sc Sc
3.1 0.8 2.3 1.0 1.2 0.7 0.4
JNJ-46281222 1 1 Sc Sc Sc Sc Sc Sc 58 47 3 142 7 3 ~617 --- 1 221 --- 1 Sc Sc
10.3 0.7 102.0 1.0
JNJ-42153605 28 1 2 226 36 2 Sc Sc Sc Sc Sc Sc 49 20 3 159 16 3 27 5 2 220 5 2 Sc Sc
5.2 1.1 9.2 0.7 5.2 1.0
JNJ-46356479 195 --- 1 220 25 2 Sc Sc Sc Sc Sc Sc 1015 387 2 131 24 4 NT NT Sc Sc
3.3 1.1 17.3 0.6
JNJ-42329001 1 1 Sc Sc Sc Sc Sc Sc 576 131 3 141 7 3 NT NT Sc Sc
15.4 0.7
JNJ-43245046 15 6 3 281 80 3 Sc Sc Sc Sc Sc Sc 82.57 21 3 130 6 3 NT NT Sc Sc
2.3 1.2 12.6 0.6
JNJ-39226421 253 100 2 115 15 2 Sc Sc Sc Sc Sc Sc 57 10 2 73 4 2 NT NT Sc Sc
1.5 0.8 0.3 0.5
JNJ-40297036 351 84 3 116 8 3 Sc Sc Sc Sc Sc Sc 329 136 3 78 3 3 n.v. --- 1 41 --- 1 Sc Sc
2.4 0.8 2.2 0.5 0.3
JNJ-41482012 175 77.89 3 78 2 3 Sc Sc Sc Sc Sc Sc n.v 3 52 6 3 n.v 2 39 3 2 Sc Sc
1.0 0.8 0.5 0.4
JNJ-52149617 281 71 3 174 17 3 Sc Sc Sc Sc 285 84 3 169 11 3 357 225 3 91 6 3 2790.74 227 2 96 6 3 Sc Sc
2.5 1.1 2.5 1.1 3.1 0.6 24.5 0.6
JNJ-35815013 Sc Sc Sc Sc Sc Sc Sc Sc 15 2 2 110 5 3 7413.1 --- 1 74 31 3 Sc Sc
0.2 0.7 85.5 0.4
JNJ-35814090 Sc Sc Sc Sc Sc Sc 834 68 3 109 13 3 n.v. 4 62 4 4 _n.v. 3 40 21 3 Sc Sc
5.3 0.9 0.5 0.3
mean SD n mean SD n mean SD n mean SD n mean SD n mean SD n
JNJ-40068782 n.v. 3 89 6 3 440 233 3 132 15 3 Sc Sc
0.4 5.0 0.7
JNJ-41329782 1059 17.2 2 80 17 3 192 34 3 152 11 3 Sc Sc
18.5 0.4 3.4 0.8
JNJ-35814376 n.v. 3 46 8 3 Sc Sc 398.1 --- 1 148 --- 1
0.2 0.8 0.8
JNJ-46281222 76 --- 1 95 10 2 Sc Sc Sc Sc
13.3 0.4
JNJ-42153605 n.v. 3 76 12 3 24 7 3 178 25 3 Sc Sc
0.4 4.6 0.8
JNJ-46356479 2344 --- 1 72 17 3 Sc Sc Sc Sc
40.0 0.4
JNJ-42329001 1259 --- 1 82 6 3 70 16 2 163 0 2 Sc Sc
33.6 0.4 1.9 0.8
JNJ-43245046 361 93 2 92 14 3 7 1 3 158 18 3 Sc Sc
55.0 0.4 1.1 0.7
JNJ-39226421 n.v. 2 49 8 2 Sc Sc Sc Sc
0.3
JNJ-40297036 n.v. 3 68 8 3 Sc Sc Sc Sc
0.5
JNJ-41482012 n.v 3 48 8 3 Sc Sc Sc Sc
0.5
JNJ-52149617 n.v. 3 51 13 3 125 34 4 118 36 4 218.8 --- 1 156 --- 1
0.3 1.1 0.7 1.9 1.0
JNJ-35815013 n.v. 4 44 8 4 199 26 3 106 9 3 Sc Sc
0.3 2.3 0.6
JNJ-35814090 631 3 63 6 3 n.v. 2 48 7 3 Sc Sc
4.0 0.5 0.4
NT Not tested
Sc Tested in screening assay 
If ratio > 3 or n.v
n.v. No value (absence of curve)
Transmembrane 6
(10) L732A(9) D725A (19) M728A (20) S731A
Extracellular loop 2/Transmembrane 5
(3) N735D (21) V736A
(11) W773A (12) F776A (13) F780A
(16) H723V
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